


**CUMULATIVE  
SUPPLEMENT 3  
MARCH 2019**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2019**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39<sup>th</sup> EDITION**

**Cumulative Supplement 3  
March 2019**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition .....	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 3  
March 2019**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                               FDA/CDER Orange Book Staff  
  Office of Generic Drugs  
  7620 Standish Place  
  Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

G AND W LABORATORIES INC  
(G AND W LABS)

ACP NIMBLE BUYER INC  
(ACP NIMBLE)

G AND W LABORATORIES INC  
(G AND W LABS INC)

ACP NIMBLE BUYER INC  
(ACP NIMBLE)

SUN PHARMA GLOBAL FZE  
(SUN PHARMA GLOBAL)

SUN PHARMACEUTICIAL  
INDUSTRIES LTD  
(SUN PHARM)

SUN PHARMA GLOBAL INC  
(SUN PHARMA GLOBAL)

SUN PHARMACEUTICIAL  
INDUSTRIES LTD  
(SUN PHARM)

#### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF	0.025MG	AB1	021342	001

	INC				
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.



Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580			
LISTED SINGLE SOURCE	2724 (13.4%)	2713 (13.2%)			
MULTISOURCE	17571 (86.6%)	17867 (86.8%)			

THERAPEUTICALLY EQUIVALENT	17483 (86.1%)	17777 (86.4%)
NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)	90 (0.4%)
EXCEPTIONS <sup>1</sup>	58 (0.3%)	58 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	25	3
NUMBER OF APPLICANTS	1133	1129

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.

CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

>A> @ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC  
 >D> AB ZYDUS PHARMS USA INC EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB RISING PHARMS 250MG A208371 001 Feb 25, 2019 Feb NEWA  
 AB WOCKHARDT BIO AG 250MG A208380 001 Feb 27, 2019 Feb NEWA

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Jan NEWA  
 + 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Jan NEWA  
 + KVK TECH INC 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Feb CAHN  
 + 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb CAHN  
 + 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A211023 001 Mar 08, 2019 Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ UPSHER SMITH LABS 325MG;5MG A206484 001 Mar 24, 2017 Jan DISC  
 @ 325MG;7.5MG A206484 002 Mar 24, 2017 Jan DISC  
 @ 325MG;10MG A206484 003 Mar 24, 2017 Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB ALEMBIC PHARMS LTD 500MG A210423 001 Feb 19, 2019 Feb NEWA  
 >A> AB CADILA 500MG A205301 001 Jan 16, 2019 Mar CAHN  
 >D> AB XYLOPIA 500MG A205301 001 Jan 16, 2019 Mar CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

>D> AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Mar DISC  
 >A> @ 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Mar DISC

>D> TABLET, EFFERVESCENT;ORAL

>D> CETYLEV

>D> + ARBOR PHARMS LLC 500MG N207916 001 Jan 29, 2016 Mar DISC  
 >A> + @ 500MG N207916 001 Jan 29, 2016 Mar DISC  
 >D> +! 2.5GM N207916 002 Jan 29, 2016 Mar DISC  
 >A> + @ 2.5GM N207916 002 Jan 29, 2016 Mar DISC

ACITRETIN

CAPSULE;ORAL

SORIATANE

+ @ STIEFEL LABS INC 17.5MG N019821 003 Aug 06, 2009 Jan DISC  
 + @ 22.5MG N019821 004 Aug 06, 2009 Jan DISC

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

>A> POWDER, METERED;INHALATION  
 >A> DUAKLIR PRESSAIR  
 >A> ASTRAZENECA PHARMS 0.4MG/INH;0.012MG/INH N210595 001 Mar 29, 2019 Mar NEWA



ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	RISING PHARMS	EQ 0.5MG BASE	A209180	001	Jan 14, 2019	Jan	CAHN
AB		EQ 1MG BASE	A209180	002	Jan 14, 2019	Jan	CAHN

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

	+ @ EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb	DISC
--	---------------	------	---------	-----	--------------	-----	------

AMBRISANTAN

TABLET; ORAL

AMBRISANTAN

>A>	AMBRISANTAN						
>A>	AB	MYLAN PHARMS INC	5MG	A208441	001	Mar 28, 2019	Mar NFTG
>A>	AB		10MG	A208441	002	Mar 28, 2019	Mar NFTG
>A>	AB	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Mar NEWA
>A>	AB		10MG	A209509	002	Apr 10, 2019	Mar NEWA
>A>	AB	SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019	Mar NEWA
>A>	AB		10MG	A208354	002	Apr 10, 2019	Mar NEWA
>A>	AB	SUN PHARM	5MG	A210784	001	Mar 28, 2019	Mar NFTG
>A>	AB		10MG	A210784	002	Mar 28, 2019	Mar NFTG
>A>	AB	WATSON LABS INC	5MG	A208252	001	Mar 28, 2019	Mar NFTG
>A>	AB		10MG	A208252	002	Mar 28, 2019	Mar NFTG
>A>	AB	ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019	Mar NFTG
>A>	AB		10MG	A210058	002	Mar 28, 2019	Mar NFTG
		LETAIRIS					
>D>		+ GILEAD	5MG	N022081	001	Jun 15, 2007	Mar CFTG
>A>	AB		5MG	N022081	001	Jun 15, 2007	Mar CFTG
>D>		+!	10MG	N022081	002	Jun 15, 2007	Mar CFTG
>A>	AB		10MG	N022081	002	Jun 15, 2007	Mar CFTG

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Feb	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

AB	+ CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb	CHRS
	AMINOCAPROIC ACID						
AB	! SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb	CHRS

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb	CTEC
@	LUITPOLD	25MG/ML	A087600	001		Feb	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@ MYLAN

EQ 2.5MG BASE; 10MG

A077375 001 May 21, 2010 Feb DISC

@

EQ 5MG BASE; 10MG

A077375 002 May 21, 2010 Feb DISC

@

EQ 5MG BASE; 20MG

A077375 003 May 21, 2010 Feb DISC

@

EQ 5MG BASE; 40MG

A079047 001 Jul 05, 2011 Feb DISC

@

EQ 10MG BASE; 20MG

A077375 004 May 21, 2010 Feb DISC

@

EQ 10MG BASE; 40MG

A079047 002 Jul 05, 2011 Feb DISC

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

>A>		+ COEPTIS	EQ 2.5MG BASE; 200MG	N210045	001	May 31, 2018	Mar CAHN
>A>			EQ 5MG BASE; 200MG	N210045	002	May 31, 2018	Mar CAHN
>A>		+!	EQ 10MG BASE; 200MG	N210045	003	May 31, 2018	Mar CAHN
>D>		+ KITOV PHARMS LTD	EQ 2.5MG BASE; 200MG	N210045	001	May 31, 2018	Mar CAHN
>D>			EQ 5MG BASE; 200MG	N210045	002	May 31, 2018	Mar CAHN
>D>		+!	EQ 10MG BASE; 200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D>	AB	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar	DISC
>A>		@	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar	DISC
>D>	AB		EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar	DISC
>A>		@	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar	DISC
>D>	AB		EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar	DISC
>A>		@	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar	DISC
>D>	AB		EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar	DISC
>A>		@	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AUGMENTIN '875'

AB	+	NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb	CAHN
----	---	-----------	---------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	NEWA
AB			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	NEWA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	NEWA

AMPHETAMINE SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

+		ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan	NEWA
+			10MG	N209905	002	Jan 30, 2019	Jan	NEWA
+			15MG	N209905	003	Jan 30, 2019	Jan	NEWA
+			20MG	N209905	004	Jan 30, 2019	Jan	NEWA

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>D>	AB	BOSCOGEN	1MG	A078944	001	Jun 28, 2010	Mar	CAHN
	AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb	CAHN
>A>	AB	KENTON	1MG	A078944	001	Jun 28, 2010	Mar	CAHN

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

AA		AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

ARIPIPIRAZOLE

AB		ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb	NEWA
AB			5MG	A207105	002	Feb 21, 2019	Feb	NEWA
AB			10MG	A207105	003	Feb 21, 2019	Feb	NEWA
AB			15MG	A207105	004	Feb 21, 2019	Feb	NEWA
AB			20MG	A207105	005	Feb 21, 2019	Feb	NEWA
AB			30MG	A207105	006	Feb 21, 2019	Feb	NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

>A>	AB	APOTEX INC	50MG	A201514	001	Mar 25, 2019	Mar	NEWA
>A>	AB		150MG	A201514	002	Mar 25, 2019	Mar	NEWA
>A>	AB		250MG	A201514	003	Mar 25, 2019	Mar	NEWA
>A>	AB	AUROBINDO PHARMA LTD	200MG	A206069	004	Dec 07, 2018	Mar	NEWA

ASENAPINE MALEATE

TABLET; SUBLINGUAL

ASENAPINE MALEATE

		@ SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Feb	DISC
		@	EQ 10MG BASE	A206107	002	Jul 17, 2018	Feb	DISC
		SAPHRIS						
+		FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CTEC
+	!		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CTEC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL  
ASPIRIN AND DIPYRIDAMOLE

>A>	AB	LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Mar NEWA
-----	----	----------------	------------	---------	-----	--------------	----------

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL  
ATENOLOL AND CHLORTHALIDONE

AB	ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB		100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL  
ATOMOXETINE HYDROCHLORIDE

>D>	@	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar CMFD
>A>	AB		18MG	A079017	001	Sep 17, 2010	Mar CMFD
>D>	@		25MG	A079017	002	Sep 17, 2010	Mar CMFD
>A>	AB		25MG	A079017	002	Sep 17, 2010	Mar CMFD
>D>	@		40MG	A079017	003	Sep 17, 2010	Mar CMFD
>A>	AB		40MG	A079017	003	Sep 17, 2010	Mar CMFD
>D>	@		60MG	A079017	004	Sep 17, 2010	Mar CMFD
>A>	AB		60MG	A079017	004	Sep 17, 2010	Mar CMFD
>D>	@		80MG	A079017	005	Sep 17, 2010	Mar CMFD
>A>	AB		80MG	A079017	005	Sep 17, 2010	Mar CMFD
>D>	@		100MG	A079017	006	Sep 17, 2010	Mar CMFD
>A>	AB		100MG	A079017	006	Sep 17, 2010	Mar CMFD

ATORVASTATIN CALCIUM

TABLET;ORAL  
ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb NEWA
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb NEWA
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb NEWA
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb NEWA
AB	MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb NEWA
AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb NEWA
AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb NEWA
AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION  
ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE				
AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb CAHN

ATROPINE

INJECTABLE;INJECTION  
ATROPINE  
@ ABBVIE  
SOLUTION;INTRAMUSCULAR  
ATROPEN

>D>	+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
>A>	+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
>A>	+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
>A>	+		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT
>A>		ATROPINE					
>A>	@	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR

ATROPINE SULFATE

SOLUTION;INTRAMUSCULAR  
ATROPEN

>D>	+	MERIDIAN MEDCL TECHN	0.25MG/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
>D>	+		0.5MG/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
>D>	+		1MG/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
>D>	+		2MG/0.7ML	N017106	001		Mar CPOT



AZACITIDINEPOWDER; INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

AP	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Feb	NEWA
----	-----------	------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
AZELASTINE HYDROCHLORIDE

>A>	AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar	NEWA
>A>	AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar	NEWA

AZITHROMYCINTABLET; ORAL  
AZITHROMYCIN

AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA

BACLOFENTABLET; ORAL  
BACLOFEN

AB	EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan	NEWA
AB		20MG	A211555	002	Feb 01, 2019	Jan	NEWA

BALSALAZIDE DISODIUMCAPSULE; ORAL  
BALSALAZIDE DISODIUM

@	MYLAN	750MG	A077807	001	Dec 28, 2007	Feb	DISC
---	-------	-------	---------	-----	--------------	-----	------

BELINOSTATPOWDER; INTRAVENOUS  
BELEODAQ

>A>	+	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar	CAHN
>D>	+	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Mar	CAHN

BENAZEPRIL HYDROCHLORIDETABLET; ORAL  
BENAZEPRIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb	CAHN
@		10MG	A076267	002	Feb 11, 2004	Feb	CAHN
@		20MG	A076267	003	Feb 11, 2004	Feb	CAHN
@		40MG	A076267	004	Feb 11, 2004	Feb	CAHN

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)  
TREANDA

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC
+		100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC

BENZONATATECAPSULE; ORAL  
BENZONATATE

AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb	NEWA
AA		150MG	A211518	002	Feb 22, 2019	Feb	NEWA
AA		200MG	A211518	003	Feb 22, 2019	Feb	NEWA
AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb	CAHN
AA		200MG	A202765	001	Jul 31, 2015	Feb	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL; TOPICAL  
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB	GLENMARK PHARMS	5%;1% BASE	A209252	001	Mar 14, 2019	Mar	NEWA
-----	----	-----------------	------------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATEINJECTABLE; INJECTION  
BENZTROPINE MESYLATE

@	LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	DISC
---	----------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

>D>		OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar	DISC
>A>	@		0.5MG	A040706	002	Feb 14, 2008	Mar	DISC
>D>			1MG	A040706	003	Feb 14, 2008	Mar	DISC

	TABLET;ORAL							
	BENZTROPINE MESYLATE							
>A>	@	1MG		A040706	003	Feb 14, 2008	Mar DISC	
	<u>BEPOTASTINE BESILATE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	BEPOTASTINE BESILATE							
AT	APOTEX INC	1.5%		A206066	001	Mar 05, 2019	Feb NFTG	
>A>	AT	MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Mar NEWA	
	BEPREVE							
AT	+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CFTG	
	<u>BETAMETHASONE DIPROPIONATE</u>							
	SPRAY;TOPICAL							
	SERNIVO							
>A>	+!	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN	
>D>	+!	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN	
>A>	<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE</u>							
>A>	OINTMENT;TOPICAL							
>A>	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE							
>A>	AB	PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Mar CAIN	
>A>	AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar CAIN	
>A>	TACLONEX							
>A>	AB	+!	LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar CAIN
>A>	SUSPENSION;TOPICAL							
>A>	TACLONEX							
>A>	+!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar CAIN	
>D>	<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE</u>							
>D>	OINTMENT;TOPICAL							
>D>	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE							
>D>	AB	PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Mar CAIN	
>D>	AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar CAIN	
>D>	TACLONEX							
>D>	AB	+!	LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar CAIN
>D>	SUSPENSION;TOPICAL							
>D>	TACLONEX							
>D>	+!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar CAIN	
	<u>BETHANECHOL CHLORIDE</u>							
	TABLET;ORAL							
	DUVOID							
>D>	AA	BI-COASTAL PHARMA	10MG	A086262	001		Mar CAHN	
>D>	AA		25MG	A086263	001		Mar CAHN	
>D>	AA		50MG	A085882	003		Mar CAHN	
>A>	AA	CHARTWELL RX	10MG	A086262	001		Mar CAHN	
>A>	AA		25MG	A086263	001		Mar CAHN	
>A>	AA		50MG	A085882	003		Mar CAHN	
	<u>BICALUTAMIDE</u>							
	TABLET;ORAL							
	BICALUTAMIDE							
AB		FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010	Feb CAHN	
AB			50MG	A079045	001	May 13, 2010	Feb CAHN	
	<u>BIMATOPROST</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	BIMATOPROST							
>A>	AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019	Mar NEWA	
	<u>BISOPROLOL FUMARATE</u>							
	TABLET;ORAL							
	BISOPROLOL FUMARATE							
	@	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jan CAHN	
	@		10MG	A075474	002	Oct 25, 2002	Jan CAHN	

BLEOMYCIN SULFATEINJECTABLE; INJECTION  
BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA
----	-------	-----------------------	---------	-----	--------------	-----	------

BORTEZOMIB>D> POWDER; INTRAVENOUS, SUBCUTANEOUS  
>D> BORTEZOMIB

>D>	+	HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC
>A>	+	@	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATE

AT	SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

BUDESONIDECAPSULE; ORAL  
BUDESONIDE

AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Feb	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL  
UCERIS

>A>	AB	+	!	SALIX	9MG	N203634	001	Jan 14, 2013	Mar	CAHN
>D>	AB	+	!	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Mar	CAHN

BUMETANIDETABLET; ORAL  
BUMETANIDE

AB	HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb	CAHN
AB		1MG	A074225	002	Apr 24, 1995	Feb	CAHN
AB		2MG	A074225	003	Apr 24, 1995	Feb	CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP	NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Feb	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

INJECTABLE; SPINAL  
BUPIVACAINE HYDROCHLORIDE

>A>	AP	B BRAUN MEDICAL INC	0.75%	A209087	001	Apr 02, 2019	Mar	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM; BUCCAL, SUBLINGUAL  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE; EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan	NEWA
AB		EQ 4MG BASE; EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan	NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan	NEWA
AB		EQ 12MG BASE; EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan	NEWA

FILM; SUBLINGUAL

>D>		CASSIPA							
>D>	+	!	TEVA PHARMS USA	EQ 16MG BASE; EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar	DISC
>A>	+	@		EQ 16MG BASE; EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar	DISC

TABLET; SUBLINGUAL  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE  
@ TEVA PHARMS USA EQ 2MG BASE; EQ 0.5MG BASE  
@ EQ 8MG BASE; EQ 2MG BASE

A091149	001	Sep 08, 2014	Jan	DISC
A091149	002	Sep 08, 2014	Jan	DISC

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
BUPROPION HYDROCHLORIDE

AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan	NEWA
AB3		300MG	A211020	002	Jan 28, 2019	Jan	NEWA

BUSULFANINJECTABLE; INJECTION  
BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN
	@ HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

>D>	AA	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC
>A>		@	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Feb	NEWA
AB			0.5MCG	A204556	002	Feb 21, 2019	Feb	NEWA

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

AB		CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan	CAHN
----	--	---------------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	A209338	001	Jan 28, 2019	Jan	NEWA
----	--	--------------------	---	---------	-----	--------------	-----	------

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBATROL

AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN
AB	+		200MG	N020712	001	Sep 30, 1997	Jan	CAHN
AB	+	!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA
AB			200MG	A205571	002	Feb 07, 2019	Jan	NEWA
AB			400MG	A205571	003	Feb 07, 2019	Jan	NEWA

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

>D>		MIKART	6MG	A207484	001	May 31, 2016	Mar	CHRS
>A>		!	6MG	A207484	001	May 31, 2016	Mar	CHRS

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

>A>		@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar	CDFR
>A>		@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar	CDFR
>A>		@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar	CDFR
>A>		@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar	CDFR
>A>		@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar	CDFR
>A>		@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	CDFR
>A>		@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar	CDFR
>A>		@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	CDFR
>A>	AP	@	450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar	CDFR
>A>		@ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar	CDFR
>A>		@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar	CDFR
>A>		@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar	CDFR
>A>		@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar	CDFR
>A>		@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar	CDFR
>A>		@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar	CDFR
>A>		@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar	CDFR
>A>		PARAPLATIN						
>A>		+ @ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CDFR
>A>		+ @	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CDFR
>A>		+ @	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CDFR
>A>		+ @	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CDFR

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>D>		@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar	CDFR
>D>		@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar	CDFR
>D>		@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar	CDFR
>D>		@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar	CDFR

>D>	INJECTABLE; IV (INFUSION)							
>D>	CARBOPLATIN							
>D>	@ FRESenius KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar	CDFR	
>D>	@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar	CDFR	
>D>	@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar	CDFR	
>D>	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar	CDFR	
>D>	AP	450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar	CDFR	
	AP HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb	CAHN	
	AP	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb	CAHN	
	AP	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb	CAHN	
	AP	600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb	CAHN	
>D>	AP MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	DISC	
>A>	@	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar	DISC	
>D>	AP	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	DISC	
>A>	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar	DISC	
>D>	AP	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	DISC	
>A>	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar	DISC	
>D>	@ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar	CDFR	
>D>	@ PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar	CDFR	
>D>	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar	CDFR	
>D>	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar	CDFR	
>D>	@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar	CDFR	
>D>	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar	CDFR	
>D>	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar	CDFR	
>D>	PARAPLATIN							
>D>	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar	CDFR	
>D>	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar	CDFR	
>D>	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar	CDFR	
>D>	@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar	CDFR	

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@ VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Feb	DISC	
------------------	-------	---------	-----	--------------	-----	------	--

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

>A> AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar	NEWA	
--------	----------------	------------	---------	-----	--------------	-----	------	--

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CASPOFUNGIN ACETATE

@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan	DISC	
@	70MG/VIAL	A209489	002	Jul 12, 2018	Jan	DISC	

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb	DISC	
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb	DISC	

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan	CTEC	
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CHRS	
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan	CTEC	
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan	DISC	
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan	DISC	

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

>A> AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar	NEWA	
>A> AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar	NEWA	

CERITINIB

>A>	TABLET;ORAL							
>A>	ZYKADIA							
>A>	+!	NOVARTIS PHARMS CORP	150MG		N211225	001	Mar 18, 2019	Mar NEWA

CETIRIZINE HYDROCHLORIDE

	SYRUP;ORAL							
	CETIRIZINE HYDROCHLORIDE							
AA	SAPTALIS PHARMS		5MG/5ML		A090191	001	Nov 12, 2009	Feb CAHN
AA	TORRENT		5MG/5ML		A078870	001	Apr 27, 2009	Jan CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	LIBRIUM							
>A>	@ BAUSCH		100MG/AMP		N012301	001		Mar CAHN
>D>	@ VALEANT PHARMS LLC		100MG/AMP		N012301	001		Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION;ORAL							
	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	@ TORRENT		4MG/5ML;5MG/5ML;60MG/5ML		A206660	001	May 15, 2017	Jan CAHN

CHLORTHALIDONE

	TABLET;ORAL							
	CHLORTHALIDONE							
AB	INVATECH PHARMA		25MG		A211063	001	Feb 26, 2019	Feb NEWA
AB			50MG		A211063	002	Feb 26, 2019	Feb NEWA

CHROMIC PHOSPHATE P-32

	INJECTABLE;INJECTION							
	PHOSPHOCOL P32							
	@ CURIUM		5mCi/ML		N017084	001		Jan CAHN

CICLESONIDE

	AEROSOL, METERED;INHALATION							
	ALVESCO							
>D>	+!	ASTRAZENECA PHARMS	0.08MG/INH		N021658	002	Jan 10, 2008	Mar CAHN
>D>	+!		0.16MG/INH		N021658	003	Jan 10, 2008	Mar CAHN
>A>	+!	COVIS PHARMA BV	0.08MG/INH		N021658	002	Jan 10, 2008	Mar CAHN
>A>	+!		0.16MG/INH		N021658	003	Jan 10, 2008	Mar CAHN
	AEROSOL, METERED;NASAL							
	ZETONNA							
>D>	+!	ASTRAZENECA PHARMS	0.037MG/INH		N202129	001	Jan 20, 2012	Mar CAHN
>A>	+!	COVIS PHARMA BV	0.037MG/INH		N202129	001	Jan 20, 2012	Mar CAHN
	SPRAY, METERED;NASAL							
	OMNARIS							
>D>	+!	ASTRAZENECA PHARMS	0.05MG/INH		N022004	001	Oct 20, 2006	Mar CAHN
>A>	+!	COVIS PHARMA BV	0.05MG/INH		N022004	001	Oct 20, 2006	Mar CAHN

CISATRACURIUM BESYLATE

	INJECTABLE;INJECTION							
	CISATRACURIUM BESYLATE							
	@ ACCORD HLTHCARE		EQ 2MG BASE/ML		A205873	001	Jun 16, 2017	Feb DISC
	CISATRACURIUM BESYLATE PRESERVATIVE FREE							
	@ ACCORD HLTHCARE		EQ 2MG BASE/ML		A205872	001	Jun 16, 2017	Feb DISC
	@		EQ 10MG BASE/ML		A205872	002	Jun 16, 2017	Feb DISC
AP	SOMERSET THERAPS LLC		EQ 2MG BASE/ML		A206791	001	Feb 20, 2019	Feb NEWA
AP			EQ 10MG BASE/ML		A206791	002	Feb 20, 2019	Feb NEWA
	NIMBEX PRESERVATIVE FREE							
AP	+!	ABBVIE	EQ 10MG BASE/ML		N020551	002	Dec 15, 1995	Feb CTEC

CLADRIBINE

>A>	TABLET;ORAL							
>A>	MAVENCLAD							
>A>	+!	EMD SERONO INC	10MG		N022561	001	Mar 29, 2019	Mar NEWA

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb	CAHN
AB		500MG	A202710	002	Jun 10, 2013	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar	DISC
>A>		@	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar	DISC

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+!	ALMIRALL	1.2%; 0.025%	N050803	001	Jul 16, 2010	Feb	CAHN
----	----	----------	--------------	---------	-----	--------------	-----	------

CLOBAZAM

TABLET; ORAL

CLOBAZAM

AB	MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan	NEWA
AB		20MG	A211711	002	Jan 30, 2019	Jan	NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb	NEWA
-----	---------------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb	NEWA
	@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb	DISC
AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan	NEWA

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb	NEWA
	@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb	DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

>A>	AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Mar	NEWA
>A>	AB		50MG	A211767	002	Apr 08, 2019	Mar	NEWA
>A>	AB		75MG	A211767	003	Apr 08, 2019	Mar	NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

@ LUITPOLD 1MG/10ML (0.1MG/ML)

A091104 001 Oct 08, 2009 Feb DISC

@ 5MG/10ML (0.5MG/ML)

A091104 002 Oct 08, 2009 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb	NEWA
-----	-------------	-------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

@ MYLAN PHARMS INC EQ 300MG BASE

A077665 002 May 17, 2012 Feb DISC

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG  
@ 7.5MG

A072514 002 May 11, 1990 Jan CMS1  
A072514 003 May 11, 1990 Jan CMS1

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT NOVITIUM PHARMA 1%

A209815 001 Feb 14, 2019 Feb NEWA

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

>A> @ HIKMA 30MG/5ML  
>D> @ WEST-WARD PHARMS INT 30MG/5ML

N202245 001 Jun 30, 2011 Mar CAHN  
N202245 001 Jun 30, 2011 Mar CAHN

TABLET; ORAL

CODEINE SULFATE

>A> AB + HIKMA 15MG  
>A> AB + 30MG  
>A> AB +! 60MG  
>D> AB + WEST-WARD PHARMS INT 15MG  
>D> AB + 30MG  
>D> AB +! 60MG

N022402 001 Jul 16, 2009 Mar CAHN  
N022402 002 Jul 16, 2009 Mar CAHN  
N022402 003 Jul 16, 2009 Mar CAHN  
N022402 001 Jul 16, 2009 Mar CAHN  
N022402 002 Jul 16, 2009 Mar CAHN  
N022402 003 Jul 16, 2009 Mar CAHN

COLCHICINE

SOLUTION; ORAL

GLOPERBA

+! ROMEG THERAPS LLC 0.6MG/5ML

N210942 001 Jan 30, 2019 Jan NEWA

TABLET; ORAL

COLCHICINE

AB ALKEM LABS LTD 0.6MG  
AB AMNEAL PHARMS 0.6MG  
AB ZYDUS PHARMS 0.6MG

A211250 001 Feb 08, 2019 Feb NEWA  
A204711 001 Sep 28, 2016 Jan NEWA  
A211519 001 Feb 19, 2019 Feb NEWA

COLCRYS

AB +! TAKEDA PHARMS USA 0.6MG

N022352 001 Jul 29, 2009 Jan CTEC

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

>D> AB GLENMARK PHARMS LTD 1.875GM/PACKET  
>A> 1.875GM/PACKET

A202190 001 Jul 16, 2018 Mar CTEC  
A202190 001 Jul 16, 2018 Mar CTEC

WELCHOL

>D> AB + DAIICHI SANKYO 1.875GM/PACKET  
>A> + @ 1.875GM/PACKET

N022362 001 Oct 02, 2009 Mar DISC  
N022362 001 Oct 02, 2009 Mar DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>D> AN MYLAN SPECIALITY LP 10MG/ML  
>A> @ 10MG/ML

A074209 001 Apr 26, 1994 Mar DISC  
A074209 001 Apr 26, 1994 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

>D> + TEVA PHARMS INTL 15MG  
>A> AB + 15MG  
+ 15MG  
>D> +! 30MG  
>A> AB +! 30MG  
+! 30MG

N021777 001 Feb 01, 2007 Mar CTEC  
N021777 001 Feb 01, 2007 Mar CTEC  
N021777 001 Feb 01, 2007 Jan CTEC  
N021777 002 Feb 01, 2007 Mar CTEC  
N021777 002 Feb 01, 2007 Mar CTEC  
N021777 002 Feb 01, 2007 Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

AB APOTEX INC 15MG  
@ 15MG  
AB 30MG  
@ 30MG  
>D> @ TWI PHARMS INC 15MG  
>A> AB 15MG  
>D> @ 30MG  
>A> AB 30MG

A206703 001 Jul 24, 2018 Feb CMFD  
A206703 001 Jul 24, 2018 Jan DISC  
A206703 002 Jul 24, 2018 Feb CMFD  
A206703 002 Jul 24, 2018 Jan DISC  
A091281 001 Jan 31, 2013 Mar CMFD  
A091281 001 Jan 31, 2013 Mar CMFD  
A091281 002 Jan 31, 2013 Mar CMFD  
A091281 002 Jan 31, 2013 Mar CMFD



CYCLOPHOSPHAMIDECAPSULE; ORAL  
CYCLOPHOSPHAMIDE

AB	CIPLA	25MG	A211608	001	Jan 18, 2019	Jan	NEWA
AB		50MG	A211608	002	Jan 18, 2019	Jan	NEWA

CYPROHEPTADINE HYDROCHLORIDESYRUP; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan	CAHN
----	---------	---------	---------	-----	--------------	-----	------

TABLET; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

AA	! HERITAGE PHARMA	4MG	A087056	001		Feb	CAHN
----	-------------------	-----	---------	-----	--	-----	------

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL  
DAKLINZA  
+ @ BRISTOL-MYERS SQUIBB EQ 90MG BASE

			N206843	003	Apr 13, 2016	Feb	DISC
--	--	--	---------	-----	--------------	-----	------

DACTINOMYCININJECTABLE; INJECTION  
DACTINOMYCIN

>D>	AP	LUITPOLD	0.5MG/VIAL	A202562	001	Aug 23, 2013	Mar	DISC
>A>		@	0.5MG/VIAL	A202562	001	Aug 23, 2013	Mar	DISC

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL  
DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb	NEWA
----	------------	------	---------	-----	--------------	-----	------

DANTROLENE SODIUMINJECTABLE; INJECTION  
DANTROLENE SODIUM

>D>	AP	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	DISC
>A>		@	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	DISC

DAPSONEGEL; TOPICAL  
ACZONE  
+! ALMIRALL 7.5%  
TABLET; ORAL  
DAPSONE

			N207154	001	Feb 24, 2016	Feb	CAHN
--	--	--	---------	-----	--------------	-----	------

AB	TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb	NEWA
AB		100MG	A209430	002	Mar 01, 2019	Feb	NEWA

DAPTOMYCINPOWDER; INTRAVENOUS  
DAPTOMYCIN

>D>	AP	CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Mar	CAHN
>A>	AP	XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar	CAHN

DECITABINEINJECTABLE; INTRAVENOUS  
DECITABINE

>A>	AP	WOCKHARDT BIO AG	50MG/VIAL	A209056	001	Apr 09, 2019	Mar	NEWA
-----	----	------------------	-----------	---------	-----	--------------	-----	------

DEFERIPRONETABLET; ORAL  
DEFERIPRONE

AB	TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	Feb	NFTG
----	---------------------	-------	---------	-----	--------------	-----	------

AB	+! APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	Feb	CFTG
----	------------------	-------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATEINJECTABLE; INJECTION  
DESMOPRESSIN ACETATE

AP	LUITPOLD	0.004MG/ML	A091374	001	Feb 14, 2019	Feb	NEWA
>D>	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD
>A>	AP	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD

## TABLET;ORAL

## DESMOPRESSIN ACETATE

AB	ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan NEWA
AB		0.2MG	A210371	002	Jan 28, 2019	Jan NEWA

DESOGESTREL; ETHINYL ESTRADIOL

## TABLET;ORAL-28

## DESOGESTREL AND ETHINYL ESTRADIOL

>D>	AB	ACCORD HLTHCARE	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Mar DISC
>A>	@		0.15MG;0.03MG	A207067	001	Sep 13, 2018	Mar DISC

DESONIDE

## AEROSOL, FOAM;TOPICAL

## VERDESO

+!	ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Feb CAHN
----	----------	-------	---------	-----	--------------	----------

## OINTMENT;TOPICAL

## DESONIDE

AB	ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan NEWA
AB	TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb NEWA

DESOXIMETASONE

## CREAM;TOPICAL

## DESOXIMETASONE

AB	RISING PHARMS	0.05%	A210980	001	Dec 21, 2018	Jan CAHN
@	ZYDUS PHARMS	0.25%	A205620	001	Sep 28, 2018	Feb DISC

DESVENLAFAXINE SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## DESVENLAFAXINE SUCCINATE

>D>	AB	YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
>A>	@		EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
>D>	AB		EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC
>A>	@		EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

## INJECTABLE;INJECTION

## DEXAMETHASONE SODIUM PHOSPHATE

AP	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CHRS
@		LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb DISC

DEXMEDETOMIDINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## DEXMEDETOMIDINE HYDROCHLORIDE

AP	CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA	
>D>	AP	LUITPOLD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	Mar DISC
>A>	@		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	Mar DISC

## SOLUTION;INTRAVENOUS

## DEXMEDETOMIDINE HYDROCHLORIDE

>D>	+	HQ SPCLT PHARMA	EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
>A>	+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
>D>	+		EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT
>A>	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DIAZEPAM

## GEL;RECTAL

## DIASTAT

+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb CAHN
+	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb CAHN
+	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb CAHN
+	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb CAHN
+	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb CAHN

## DIASTAT ACUDIAL

+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb CAHN
+!		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb CAHN

## INJECTABLE; INJECTION

## DIAZEPAM

>A>	AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar NEWA
>D>	!	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar CTEC
>A>	AP	!	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar CTEC

DICLOFENAC

## CAPSULE; ORAL

## ZORVOLEX

+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Feb CAHN

DICLOFENAC EPOLAMINE

## SYSTEM; TOPICAL

## LICART

+	@	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	---	---------------	------	---------	-----	--------------	----------

DICYCLOMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DICYCLOMINE HYDROCHLORIDE

	@	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb DISC
AP		CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan NEWA
AP		FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan NEWA
AP		NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan NEWA
AP		SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb CAHN

DIHYDROERGOTAMINE MESYLATE

## SPRAY, METERED; NASAL

## MIGRANAL

+	!	VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan CPOT
---	---	---------	-------------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## CARDIZEM CD

AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb CAHN
AB3	+	!	360MG	N020062	005	Aug 24, 1999	Feb CAHN

## DILTIAZEM HYDROCHLORIDE

>D>	AB3	PAR PHARM	360MG	A209766	001	May 30, 2018	Mar DISC
>A>		@	360MG	A209766	001	May 30, 2018	Mar DISC

## TIAZAC

AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+	!	420MG	N020401	006	Oct 16, 1998	Feb CAHN

## TABLET; ORAL

## CARDIZEM

>A>	AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar CAHN
>A>	AB	+		60MG	N018602	002	Nov 05, 1982	Mar CAHN
>A>	AB	+		90MG	N018602	003	Dec 08, 1986	Mar CAHN
>A>	AB	+	!	120MG	N018602	004	Dec 08, 1986	Mar CAHN
>D>	AB	+	VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Mar CAHN
>D>	AB	+		60MG	N018602	002	Nov 05, 1982	Mar CAHN
>D>	AB	+		90MG	N018602	003	Dec 08, 1986	Mar CAHN
>D>	AB	+	!	120MG	N018602	004	Dec 08, 1986	Mar CAHN

## TABLET, EXTENDED RELEASE; ORAL

## CARDIZEM LA

>A>	AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar CAHN
>A>	AB	+		180MG	N021392	002	Feb 06, 2003	Mar CAHN
>A>	AB	+		240MG	N021392	003	Feb 06, 2003	Mar CAHN
>A>	AB	+		300MG	N021392	004	Feb 06, 2003	Mar CAHN
>A>	AB	+		360MG	N021392	005	Feb 06, 2003	Mar CAHN
>A>	AB	+	!	420MG	N021392	006	Feb 06, 2003	Mar CAHN
>D>	AB	+	VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Mar CAHN
>D>	AB	+		180MG	N021392	002	Feb 06, 2003	Mar CAHN
>D>	AB	+		240MG	N021392	003	Feb 06, 2003	Mar CAHN
>D>	AB	+		300MG	N021392	004	Feb 06, 2003	Mar CAHN
>D>	AB	+		360MG	N021392	005	Feb 06, 2003	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL  
CARDIZEM LA

>D> AB +! 420MG N021392 006 Feb 06, 2003 Mar CAHN

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL  
DIMETHYL SULFOXIDE

>D> AT MYLAN INSTITUTIONAL 50% A076185 001 Nov 29, 2002 Mar DISC

>A> @ 50% A076185 001 Nov 29, 2002 Mar DISC

## RIMS0-50

>D> AT +! MYLAN INSTITUTIONAL 50% N017788 001 Mar CTEC

>A> +! 50% N017788 001 Mar CTEC

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

>D> AP CIPLA 20MG/2ML (10MG/ML) A209634 001 Aug 24, 2018 Mar DISC

>A> @ 20MG/2ML (10MG/ML) A209634 001 Aug 24, 2018 Mar DISC

>D> AP 80MG/8ML (10MG/ML) A209634 002 Aug 24, 2018 Mar DISC

>A> @ 80MG/8ML (10MG/ML) A209634 002 Aug 24, 2018 Mar DISC

>D> AP 160MG/16ML (10MG/ML) A209634 003 Aug 24, 2018 Mar DISC

>A> @ 160MG/16ML (10MG/ML) A209634 003 Aug 24, 2018 Mar DISC

>D> AP EAGLE PHARMS 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Mar CAHN

>D> AP 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Mar CAHN

>D> AP 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Mar CAHN

>A> AP MYLAN LABS LTD 160MG/8ML (20MG/ML) A208137 001 Apr 01, 2019 Mar NEWA

>A> AP TEIKOKU PHARMA 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Mar CAHN

>A> AP 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Mar CAHN

>A> AP 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Mar CAHN

SOLUTION; INTRAVENOUS  
DOCETAXEL

AP SUN PHARMA GLOBAL 20MG/ML (20MG/ML) N022534 003 Jan 08, 2019 Jan NEWA

AP 80MG/4ML (20MG/ML) N022534 004 Jan 08, 2019 Jan NEWA

AP 160MG/8ML (20MG/ML) N022534 005 Jan 08, 2019 Jan NEWA

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

AB AUROBINDO PHARMA LTD 0.125MG A210740 001 Jan 22, 2019 Jan NEWA

AB 0.25MG A210740 002 Jan 22, 2019 Jan NEWA

AB 0.5MG A210740 003 Jan 22, 2019 Jan NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL  
DONEPEZIL HYDROCHLORIDE

>A> AB CADILA 5MG A090100 001 Oct 24, 2012 Mar CAHN

>A> AB 10MG A090100 002 Oct 24, 2012 Mar CAHN

>D> AB OSMOTICA PHARM US 23MG A203114 001 Jan 26, 2016 Mar DISC

>A> @ 23MG A203114 001 Jan 26, 2016 Mar DISC

>D> AB ZYDUS PHARMS USA INC 5MG A090100 001 Oct 24, 2012 Mar CAHN

>D> AB 10MG A090100 002 Oct 24, 2012 Mar CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DOPAMINE HYDROCHLORIDE

@ LUITPOLD 40MG/ML

A070799 001 Feb 11, 1987 Feb DISC

@ 80MG/ML

A070820 001 Feb 11, 1987 Feb DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

AT FDC LTD EQ 2% BASE A205294 001 Jan 24, 2019 Jan NEWA

>D> AT LUITPOLD EQ 2% BASE A079186 001 Nov 18, 2009 Mar DISC

>A> @ EQ 2% BASE A079186 001 Nov 18, 2009 Mar DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION  
DOPRAM

>A> AP +! HIKMA 20MG/ML N014879 001 Mar CAHN

>D> AP +! WEST-WARD PHARMS INT 20MG/ML N014879 001 Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar	NEWA
	AB	PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987	Jan	CMFD
	AB		EQ 25MG BASE	A071437	001	Nov 09, 1987	Jan	CMFD
	AB		EQ 75MG BASE	A071608	001	Nov 09, 1987	Jan	CMFD

TABLET;ORAL

SILENOR

+	PERNIX		EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb	CAHN
+	!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb	CAHN

DOXYCYCLINE

CAPSULE;ORAL

MONODOX

AB	+	ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb	CAHN
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb	CAHN
AB	+	!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb	CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+	@	ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb	CAHN
---	---	----------	--------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

>D>	AB	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar	DISC
>A>		@	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar	DISC
>D>	AB		EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar	DISC
>A>		@	EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar	DISC

TABLET;ORAL

ACTICLATE

AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb	CAHN
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb	CAHN
		DOXYCYCLINE HYCLATE						
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

>A>	AB	HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar	NEWA
		TABLET;ORAL-28						
		KEMEYA						
AB		SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb	NEWA
----	--	-------------------	--------------	---------	-----	--------------	-----	------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB		CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN
		@ RISING PHARMS	0.5MG	A202530	001	Nov 20, 2015	Feb	DISC

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

@	AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Feb	DISC
---	----------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>		MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Mar	NEWA
-----	--	---------------------	-------------------	---------	-----	--------------	-----	------

EFINACONAZOLESOLUTION;TOPICAL  
JUBLIA

+! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CAHN

ELTROMBOPAG OLAMINETABLET;ORAL  
PROMACTA

+ @ NOVARTIS PHARMS CORP EQ 100MG ACID N022291 005 Nov 16, 2012 Feb DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO 100MG;150MG A209721 001 Aug 22, 2018 Feb DISC

@ 133MG;200MG A209721 002 Aug 22, 2018 Feb DISC

@ 167MG;250MG A209721 003 Aug 22, 2018 Feb DISC

@ 200MG;300MG A209721 004 Aug 22, 2018 Feb DISC

TRUVADA

+ GILEAD 100MG;150MG N021752 002 Mar 10, 2016 Feb CTEC

+ 133MG;200MG N021752 003 Mar 10, 2016 Feb CTEC

+ 167MG;250MG N021752 004 Mar 10, 2016 Feb CTEC

ENALAPRIL MALEATE

&gt;D&gt; FOR SOLUTION;ORAL

&gt;D&gt; EPANED KIT

&gt;D&gt; +! SILVERGATE PHARMS 1MG/ML N204308 001 Aug 13, 2013 Mar DISC

&gt;A&gt; + @ 1MG/ML N204308 001 Aug 13, 2013 Mar DISC

TABLET;ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA 2.5MG A075621 001 Aug 22, 2000 Feb CAHN

@ 5MG A075621 002 Aug 22, 2000 Feb CAHN

@ 10MG A075621 003 Aug 22, 2000 Feb CAHN

@ 20MG A075621 004 Aug 22, 2000 Feb CAHN

AB HERITAGE PHARMA 2.5MG A075479 001 Aug 22, 2000 Feb CAHN

AB 5MG A075479 002 Aug 22, 2000 Feb CAHN

AB 10MG A075479 003 Aug 22, 2000 Feb CAHN

AB 20MG A075479 004 Aug 22, 2000 Feb CAHN

@ MYLAN 10MG A075480 003 Aug 22, 2000 Feb DISC

VASOTEC

&gt;A&gt; AB + BAUSCH 2.5MG N018998 005 Jul 26, 1988 Mar CAHN

&gt;A&gt; AB + 5MG N018998 001 Dec 24, 1985 Mar CAHN

&gt;A&gt; AB + 10MG N018998 002 Dec 24, 1985 Mar CAHN

&gt;A&gt; AB +! 20MG N018998 003 Dec 24, 1985 Mar CAHN

&gt;D&gt; AB + VALEANT PHARMS NORTH 2.5MG N018998 005 Jul 26, 1988 Mar CAHN

&gt;D&gt; AB + 5MG N018998 001 Dec 24, 1985 Mar CAHN

&gt;D&gt; AB + 10MG N018998 002 Dec 24, 1985 Mar CAHN

&gt;D&gt; AB +! 20MG N018998 003 Dec 24, 1985 Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

VASERETIC

&gt;A&gt; AB + BAUSCH 5MG;12.5MG N019221 003 Jul 12, 1995 Mar CAHN

&gt;A&gt; AB +! 10MG;25MG N019221 001 Oct 31, 1986 Mar CAHN

&gt;D&gt; AB + VALEANT INTL 5MG;12.5MG N019221 003 Jul 12, 1995 Mar CAHN

&gt;D&gt; AB +! 10MG;25MG N019221 001 Oct 31, 1986 Mar CAHN

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

&gt;A&gt; AB AMPHASTAR PHARMS INC 300MG/3ML (100MG/ML) A208600 001 Mar 14, 2019 Mar NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

&gt;A&gt; AB MYLAN PHARMS INC 0.5MG A206226 001 Mar 26, 2019 Mar NEWA

&gt;A&gt; AB 1MG A206226 002 Mar 26, 2019 Mar NEWA

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS  
EPINEPHRINE (AUTOINJECTOR)

>D>	AB	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar	DISC	
>A>		@	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar	DISC	
		EPIPEN JR.							
>D>	AB	+!	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar	CTEC
>A>		+!		0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar	CTEC
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
		ADRENALIN							
AP	+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan	CDFR	
	+!		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan	CDFR	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION  
EPIRUBICIN HYDROCHLORIDE

>D>	AP	FRESENIUS KABI USA	150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar	CTEC
>A>			150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar	CTEC
>D>	AP	HOSPIRA	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007	Mar	DISC
>A>		@	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007	Mar	DISC
>D>	AP		150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007	Mar	DISC
>A>		@	150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007	Mar	DISC
>D>	AP		200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007	Mar	DISC
>A>		@	200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007	Mar	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

AP		BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan	CAHN
AP			75MG/100ML	A208554	002	Nov 23, 2018	Jan	CAHN
AP		HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan	NEWA
AP			75MG/100ML	A209864	002	Jan 25, 2019	Jan	NEWA
>A>	AP	USV	2MG/ML	A204361	001	Mar 14, 2019	Mar	NEWA
AP			2MG/ML	A204362	001	Mar 11, 2019	Feb	NEWA
>A>	AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb	CMFD	
AB			EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb	CMFD	
AB			EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb	CMFD	
>D>		@ TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar	CMFD	
>A>	AB		EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar	CMFD	
>D>		@	EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar	CMFD	
>A>	AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar	CMFD	
		TARCEVA							
>D>	AB	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar	CAHN
>A>	AB	+		EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar	CAHN
	AB	+		EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb	CTEC
>D>	AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar	CAHN
>A>	AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar	CAHN
	AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb	CTEC
>D>	AB	+!		EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar	CAHN
>A>	AB	+!		EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar	CAHN
	AB	+!		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb	CTEC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

>A>	AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar	NEWA
-----	----	---------------------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

SOLUTION; TOPICAL  
ERYTHRA-DERM

		@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb	CAHN
--	--	-------------------	----	---------	-----	--------------	-----	------

>A>	<u>ESKETAMINE HYDROCHLORIDE</u>				
>A>	SPRAY;NASAL				
>A>	SPRAVATO				
>A>	+!	JANSSEN PHARMS	EQ 28MG BASE	N211243 001	Mar 05, 2019 Mar NEWA
	<u>ESMOLOL HYDROCHLORIDE</u>				
	INJECTABLE; INJECTION				
	ESMOLOL HYDROCHLORIDE				
>D> AP		LUITPOLD	10MG/ML	A201126 001	Feb 20, 2015 Mar DISC
>A>	@		10MG/ML	A201126 001	Feb 20, 2015 Mar DISC
	<u>ESOMEPRAZOLE MAGNESIUM</u>				
	CAPSULE, DELAYED REL PELLETS;ORAL				
	ESOMEPRAZOLE MAGNESIUM				
>A> AB		AMNEAL PHARMS NY	EQ 20MG BASE	A209647 001	Apr 10, 2019 Mar NEWA
>A> AB			EQ 40MG BASE	A209647 002	Apr 10, 2019 Mar NEWA
>D> AB		HEC PHARM	EQ 20MG BASE	A207265 002	May 18, 2018 Mar DISC
>A>	@		EQ 20MG BASE	A207265 002	May 18, 2018 Mar DISC
>D> AB			EQ 40MG BASE	A207265 001	May 18, 2018 Mar DISC
>A>	@		EQ 40MG BASE	A207265 001	May 18, 2018 Mar DISC
	<u>ESTRADIOL</u>				
	FILM, EXTENDED RELEASE;TRANSDERMAL				
	ESTRADIOL				
AB1		AMNEAL PHARMS LLC	0.025MG/24HR	A211293 001	Feb 04, 2019 Jan NEWA
AB1			0.0375MG/24HR	A211293 002	Feb 04, 2019 Jan NEWA
AB1			0.05MG/24HR	A211293 003	Feb 04, 2019 Jan NEWA
AB1			0.075MG/24HR	A211293 004	Feb 04, 2019 Jan NEWA
AB1			0.1MG/24HR	A211293 005	Feb 04, 2019 Jan NEWA
	GEL;TRANSDERMAL				
	DIVIGEL				
	+!	VERTICAL PHARMS LLC	0.1%	N022038 001	Jun 04, 2007 Jan CHRS
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>				
	TABLET;ORAL				
	ESTRADIOL AND NORETHINDRONE ACETATE				
>D> AB		ACCORD HLTHCARE	1MG;0.5MG	A210233 001	Feb 28, 2018 Mar DISC
>A>	@		1MG;0.5MG	A210233 001	Feb 28, 2018 Mar DISC
>A> AB		NOVAST LABS	0.5MG;0.1MG	A210612 001	Apr 03, 2019 Mar NEWA
>A> AB			1MG;0.5MG	A210612 002	Apr 03, 2019 Mar NEWA
	<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>				
	TABLET;ORAL				
	CENESTIN				
	+ @	ASPEN	0.3MG	N020992 001	Jun 21, 2002 Feb CAHN
	+ @		0.45MG	N020992 005	Feb 05, 2004 Feb CAHN
	+ @		0.625MG	N020992 002	Mar 24, 1999 Feb CAHN
	+ @		0.9MG	N020992 003	Mar 24, 1999 Feb CAHN
	+ @		1.25MG	N020992 004	Mar 13, 2000 Feb CAHN
	<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>				
	TABLET;ORAL				
	ENJUUIA				
	@	ASPEN	0.3MG	N021443 001	Dec 20, 2004 Feb CAHN
	@		0.45MG	N021443 002	Dec 20, 2004 Feb CAHN
	@		0.625MG	N021443 003	May 10, 2004 Feb CAHN
	@		0.9MG	N021443 005	Apr 27, 2007 Feb CAHN
	@		1.25MG	N021443 004	May 10, 2004 Feb CAHN
	<u>ETHACRYNATE SODIUM</u>				
	INJECTABLE; INJECTION				
	EDECIN				
>A> AP	+!	BAUSCH	EQ 50MG BASE/VIAL	N016093 001	Mar CAHN
>D> AP	+!	VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093 001	Mar CAHN
AP	+!		EQ 50MG BASE/VIAL	N016093 001	Jan CAHN



ETHACRYNIC ACID

TABLET; ORAL

EDECIN

>A>	AB	+!	BAUSCH	25MG	N016092	001		Mar	CAHN
>A>		@		50MG	N016092	002		Mar	CAHN
>D>	AB	+!	VALEANT PHARMS INTL	25MG	N016092	001		Mar	CAHN
	AB	+!		25MG	N016092	001		Jan	CAHN
>D>		@		50MG	N016092	002		Mar	CAHN
		@		50MG	N016092	002		Jan	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

LO-MALMOREDE

AB			NOVAST LABS	0.035MG;1MG	A209548	001	Feb 11, 2019	Jan	NEWA
----	--	--	-------------	-------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SYLEVIA

AB			SUN PHARM	0.03MG;0.15MG	A202988	001	Feb 06, 2019	Jan	NEWA
----	--	--	-----------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORTREL 1/35-28

>D>	AB		BARR	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar	CHRS
>A>	AB	!		0.035MG;1MG	A072696	001	Feb 28, 1992	Mar	CHRS
>D>			ORTHO-NOVUM 1/35-28						
>D>	AB	+!	JANSSEN PHARMS	0.035MG;1MG	N017919	002		Mar	DISC
>A>		+ @		0.035MG;1MG	N017919	002		Mar	DISC
			TABLET, CHEWABLE; ORAL						
>D>			FEMCON FE						
>D>	AB	+!	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Mar	DISC
>A>		+ @		0.035MG;0.4MG	N021490	001	Nov 14, 2003	Mar	DISC
			NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>D>	AB		MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar	CHRS
>A>	AB	!		0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar	CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

HAILEY 1.5/30

AB			GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	Jan	CDFR
			LOESTRIN 21 1.5/30						
AB	+		APIL	0.03MG;1.5MG	N017875	001		Jan	CRLD
			LOESTRIN 21 1/20						
AB	+		APIL	0.02MG;1MG	N017876	001		Jan	CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD

0.025MG,0.025MG,0.025MG;0.18MG,0.2

A202132	001	Sep 09, 2015	Jan	DISC
---------	-----	--------------	-----	------

15MG,0.25MG

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL

ANNOVERA

+ @	THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Feb	DISC
-----	--------------------	--------------------------	---------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB			STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb	NEWA
----	--	--	----------------	-------	---------	-----	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ LUITPOLD

2MG/ML

A078867	001	Dec 22, 2009	Feb	DISC
---------	-----	--------------	-----	------

EVEROLIMUSTABLET; ORAL  
ZORTRESS

>A>	+	NOVARTIS	1MG	N021560	004	Aug 10, 2018	Mar	NEWA
-----	---	----------	-----	---------	-----	--------------	-----	------

EXEMESTANETABLET; ORAL  
EXEMESTANE

AB		BRECKENRIDGE PHARM	25MG	A211031	001	Feb 21, 2019	Feb	NEWA
----	--	--------------------	------	---------	-----	--------------	-----	------

FENOFIBRATECAPSULE; ORAL  
FENOFIBRATE (MICRONIZED)

AB		AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan	CAHN
AB			134MG	A207805	002	Nov 16, 2017	Jan	CAHN
AB			200MG	A207805	003	Nov 16, 2017	Jan	CAHN

TABLET; ORAL  
FENOFIBRATE

AB		AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan	CAHN
AB			160MG	A207803	002	Dec 19, 2017	Jan	CAHN
	@	GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb	DISC
	@		160MG	A210606	002	Aug 17, 2018	Feb	DISC
AB		ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan	NEWA
AB			160MG	A209660	002	Feb 11, 2019	Jan	NEWA

FENOGLIDE

>A>	AB	+	SALIX	40MG	N022118	001	Aug 10, 2007	Mar	CAHN
>A>	AB	+	!	120MG	N022118	002	Aug 10, 2007	Mar	CAHN
>D>	AB	+	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Mar	CAHN
>D>	AB	+	!	120MG	N022118	002	Aug 10, 2007	Mar	CAHN

FENOFIBRIC ACIDTABLET; ORAL  
FIBRICOR

	+	ATHENA	35MG	N022418	001	Aug 14, 2009	Feb	CAHN
	+	!	105MG	N022418	002	Aug 14, 2009	Feb	CAHN

FLOXURIDINEINJECTABLE; INJECTION  
FLOXURIDINE

>D>	AP		LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Mar	DISC
>A>		@		500MG/VIAL	A203008	001	Nov 22, 2017	Mar	DISC

FLUCYTOSINECAPSULE; ORAL  
ANCOBON

AB	+	BAUSCH	250MG	N017001	001		Feb	CAHN
AB	+	!	500MG	N017001	002		Feb	CAHN

FLUOCINOLONE ACETONIDESOLUTION; TOPICAL  
FLUOCINOLONE ACETONIDE

>D>	AT		ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar	DISC
>A>		@		0.01%	A208386	001	Oct 21, 2016	Mar	DISC
	AT		ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan	NEWA
	AT		GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan	CMFD
	AT		LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb	CAHN

FLUOCINONIDECREAM; TOPICAL  
FLUOCINONIDE

>A>	AB	@	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb	DISC
			TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar	NEWA

SOLUTION; TOPICAL  
FLUOCINONIDE

>A>	AT		TELIGENT PHARMA INC	0.05%	A207554	001	Mar 18, 2019	Mar	NEWA
-----	----	--	---------------------	-------	---------	-----	--------------	-----	------

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC  
FLAREX

+! EYEVANCE 0.1% N019079 001 Feb 11, 1986 Feb CAHN

FLUOROURACILCREAM;TOPICAL  
FLUOROPLEX

+! ALMIRALL 1% N016988 001 Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

@ BEXIMCO PHARMS USA EQ 10MG BASE A075807 001 Jan 29, 2002 Feb CAHN

@ EQ 20MG BASE A075807 002 Jan 29, 2002 Feb CAHN

&gt;D&gt; AB PAR PHARM EQ 40MG BASE A076922 003 Dec 16, 2004 Mar DISC

&gt;A&gt; @ EQ 40MG BASE A076922 003 Dec 16, 2004 Mar DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB APPCO PHARMA LLC EQ 10MG BASE A211696 001 Jan 30, 2019 Jan NEWA

AB EQ 20MG BASE A211696 002 Jan 30, 2019 Jan NEWA

AB DR REDDYS LABS LTD EQ 60MG BASE A211721 001 Jan 25, 2019 Jan NEWA

AB LUPIN LTD EQ 60MG BASE A211632 001 Feb 08, 2019 Feb NEWA

&gt;A&gt; AB SCIEGEN PHARMS INC EQ 10MG BASE A210935 001 Mar 20, 2019 Mar NEWA

&gt;A&gt; AB EQ 20MG BASE A210935 002 Mar 20, 2019 Mar NEWA

FLURANDRENOLIDECREAM;TOPICAL  
CORDRAN SP

+! ALMIRALL 0.025% N012806 003 Feb CAHN

AT +! 0.05% N012806 002 Feb CAHN

LOTION;TOPICAL  
CORDRAN

AT +! ALMIRALL 0.05% N013790 001 Feb CAHN

OINTMENT;TOPICAL  
CORDRAN

+ @ ALMIRALL 0.025% N012806 004 Feb CAHN

AT +! 0.05% N012806 001 Feb CAHN

TAPE;TOPICAL  
CORDRAN

+! ALMIRALL 0.004MG/SQ CM N016455 001 Feb CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

ADV AIR DISKUS 100/50

AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH N021077 001 Aug 24, 2000 Jan CFTG

ADV AIR DISKUS 250/50

AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH N021077 002 Aug 24, 2000 Jan CFTG

ADV AIR DISKUS 500/50

AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH N021077 003 Aug 24, 2000 Jan CFTG

WIXELA INHUB

AB MYLAN PHARMS INC 0.1MG/INH;EQ 0.05MG BASE/INH A208891 001 Jan 30, 2019 Jan NFTG

AB 0.25MG/INH;EQ 0.05MG BASE/INH A208891 002 Jan 30, 2019 Jan NFTG

AB 0.5MG/INH;EQ 0.05MG BASE/INH A208891 003 Jan 30, 2019 Jan NFTG

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA INVATECH PHARMA 1MG A211064 001 Mar 08, 2019 Feb NEWA

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

FOSPHENYTOIN SODIUM

@ LUITPOLD EQ 50MG PHENYTOIN NA/ML A078277 001 Aug 06, 2007 Feb DISC

@ EQ 50MG PHENYTOIN NA/ML A090099 001 May 13, 2010 Feb DISC

FULVESTRANTINJECTABLE; INTRAMUSCULAR  
FASLODEX

AP	+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Feb CFTG
AP		AMNEAL PHARMS CO	50MG/ML	A210044	001	Mar 04, 2019	Feb NFTG

FUROSEMIDETABLET; ORAL  
FUROSEMIDE

AB		HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
AB			40MG	N018413	002	Nov 30, 1983	Feb CAHN

GABAPENTINTABLET; ORAL  
GABAPENTIN

>D>	AB	LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
>A>		@	600MG	A209306	001	Aug 24, 2018	Mar DISC
>D>	AB		800MG	A209306	002	Aug 24, 2018	Mar DISC
>A>		@	800MG	A209306	002	Aug 24, 2018	Mar DISC

GALLIUM CITRATE GA-67INJECTABLE; INJECTION  
GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001		Jan CAHN
----	--	--------	---------	---------	-----	--	----------

GANCICLOVIR SODIUMINJECTABLE; INJECTION  
GANCICLOVIR

		@ LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Feb DISC
--	--	------------	--------------------	---------	-----	--------------	----------

GANIRELIX ACETATEINJECTABLE; INJECTION  
GANIRELIX ACETATE

>D>	AP	+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001	Jul 29, 1999	Mar CPOT
>A>	AP	+		250MCG/0.5ML	N021057	001	Jul 29, 1999	Mar CPOT
>A>	AP		SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	Mar CPOT
>D>	AP		SUN PHARM INDS LTD	EQ 250MCG BASE/0.5ML	A204246	001	Nov 30, 2018	Mar CPOT

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan CAHN
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan CAHN
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan CAHN
AP		INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb NEWA
AP			1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb NEWA
AP			2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb NEWA
		@ LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb DISC
		@	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb DISC
AP		SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb NEWA
AP			EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb NEWA

GLASDEGIB MALEATETABLET; ORAL  
DAURISMO

	+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAIN
	+		EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDETABLET; ORAL  
GLIMEPIRIDE

>A>	AB	MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
>A>	AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
>A>			3MG	A091220	003	Jun 29, 2012	Mar CAHN
>A>	AB		4MG	A091220	004	Jun 29, 2012	Mar CAHN
>A>			6MG	A091220	005	Jun 29, 2012	Mar CAHN
>A>	AB		8MG	A091220	006	Jun 29, 2012	Mar CAHN
>D>	AB	VIVA HLTHCARE	1MG	A091220	001	Jun 29, 2012	Mar CAHN
>D>	AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
>D>			3MG	A091220	003	Jun 29, 2012	Mar CAHN

		TABLET;ORAL							
		GLIMEPIRIDE							
>D>	AB		4MG	A091220	004	Jun 29, 2012	Mar	CAHN	
>D>			6MG	A091220	005	Jun 29, 2012	Mar	CAHN	
>D>	AB		8MG	A091220	006	Jun 29, 2012	Mar	CAHN	
		<u>GLIPIZIDE</u>							
		TABLET;ORAL							
		GLIPIZIDE							
		@ BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb	CAHN	
		@	10MG	A074542	002	Jun 20, 1995	Feb	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		GLIPIZIDE							
		@ MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	Feb	DISC	
		@	5MG	A202298	002	May 19, 2015	Feb	DISC	
		@	10MG	A202298	003	May 19, 2015	Feb	DISC	
		<u>GLYBURIDE</u>							
		TABLET;ORAL							
		GLYBURIDE							
AB1		ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Feb	NEWA	
AB1			2.5MG	A206483	002	Feb 22, 2019	Feb	NEWA	
AB1			5MG	A206483	003	Feb 22, 2019	Feb	NEWA	
		<u>GLYCEROL PHENYLBUTYRATE</u>							
		LIQUID;ORAL							
		RAVICTI							
	+	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	CAHN	
		<u>GLYCOPYRROLATE</u>							
		INJECTABLE;INJECTION							
		GLYCOPYRROLATE							
>A>	AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar	NEWA	
		TABLET;ORAL							
		GLYCOPYRROLATE							
>D>	AA	BOSCOGEN	1MG	A091182	001	Feb 03, 2014	Mar	CAHN	
>D>	AA		2MG	A091182	002	Feb 03, 2014	Mar	CAHN	
>A>	AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar	CAHN	
>A>	AA		2MG	A091182	002	Feb 03, 2014	Mar	CAHN	
		<u>GRANISETRON HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		GRANISETRON HYDROCHLORIDE							
		@ LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb	DISC	
		TABLET;ORAL							
		GRANISETRON HYDROCHLORIDE							
		@ TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007	Jan	DISC	
AB	!	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Jan	CHRS	
		<u>HALOBETASOL PROPIONATE</u>							
		LOTION;TOPICAL							
		BRYHALI							
	+	DOW PHARM	0.01%	N209355	001	Nov 06, 2018	Jan	CHRS	
	+		0.01%	N209355	001	Nov 06, 2018	Jan	CRLD	
		<u>HALOPERIDOL</u>							
		TABLET;ORAL							
		HALOPERIDOL							
>D>		@ ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Mar	CAHN	
>D>		@	1MG	A071157	001	Jan 02, 1987	Mar	CAHN	
>D>		@	2MG	A071172	001	Jan 02, 1987	Mar	CAHN	
>D>		@	5MG	A071212	001	Jan 07, 1988	Mar	CAHN	
>D>		@	10MG	A071173	001	Jan 07, 1988	Mar	CAHN	
>D>		@	20MG	A071177	001	Jan 07, 1988	Mar	CAHN	
>A>		@ INNOGENIX	0.5MG	A071156	001	Jan 02, 1987	Mar	CAHN	
>A>		@	1MG	A071157	001	Jan 02, 1987	Mar	CAHN	
>A>		@	2MG	A071172	001	Jan 02, 1987	Mar	CAHN	
>A>		@	5MG	A071212	001	Jan 07, 1988	Mar	CAHN	
>A>		@	10MG	A071173	001	Jan 07, 1988	Mar	CAHN	
>A>		@	20MG	A071177	001	Jan 07, 1988	Mar	CAHN	
		!	MYLAN	A070278	001	Jun 10, 1986	Jan	CTEC	
AB	!		2MG	A070278	001	Jun 10, 1986	Jan	CHRS	

	TABLET; ORAL							
	HALOPERIDOL							
	@ SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan	DISC	
	<u>HEPARIN SODIUM</u>							
	INJECTABLE; INJECTION							
	HEPARIN SODIUM							
AP	+!	HIKMA	1,000 UNITS/ML	N017037	001		Feb	CAHN
AP	+!		5,000 UNITS/ML	N017037	002		Feb	CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb	CAHN
AP	+!		10,000 UNITS/ML	N017037	003		Feb	CAHN
	<u>HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE</u>							
	SYRUP; ORAL							
	HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
	@ TORRENT	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Jan	CAHN	
	<u>HYDRALAZINE HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	HYDRALAZINE HYDROCHLORIDE							
	@ LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	DISC	
	<u>HYDROCHLOROTHIAZIDE; LISINAPRIL</u>							
	TABLET; ORAL							
	LISINAPRIL AND HYDROCHLOROTHIAZIDE							
AB	HERITAGE PHARMA	12.5MG; 10MG	A075776	001	Jul 01, 2002	Feb	CAHN	
AB		12.5MG; 20MG	A075776	002	Jul 01, 2002	Feb	CAHN	
AB		25MG; 20MG	A075776	003	Jul 01, 2002	Feb	CAHN	
	<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL</u>							
	TABLET; ORAL							
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
AB	ACCORD HLTHCARE	12.5MG; 20MG	A209281	001	Feb 07, 2019	Jan	NEWA	
AB		12.5MG; 40MG	A209281	002	Feb 07, 2019	Jan	NEWA	
AB		25MG; 40MG	A209281	003	Feb 07, 2019	Jan	NEWA	
	<u>HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE</u>							
	TABLET; ORAL							
	QUINARETIC							
AB	LUPIN	12.5MG; EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb	CAHN	
AB		12.5MG; EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb	CAHN	
AB		25MG; EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb	CAHN	
	<u>HYDROCHLOROTHIAZIDE; TELMISARTAN</u>							
	TABLET; ORAL							
	TELMISARTAN AND HYDROCHLOROTHIAZIDE							
AB	GLENMARK PHARMS LTD	12.5MG; 40MG	A202544	001	Mar 04, 2019	Feb	NEWA	
AB		12.5MG; 80MG	A202544	002	Mar 04, 2019	Feb	NEWA	
AB		25MG; 80MG	A202544	003	Mar 04, 2019	Feb	NEWA	
	<u>HYDROCHLOROTHIAZIDE; TRIAMTERENE</u>							
	CAPSULE; ORAL							
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE							
AB	ZYDUS PHARMS	25MG; 37.5MG	A208358	001	Feb 11, 2019	Jan	NEWA	
	<u>HYDROCHLOROTHIAZIDE; VALSARTAN</u>							
	TABLET; ORAL							
	VALSARTAN AND HYDROCHLOROTHIAZIDE							
>A>	AB	ZYDUS PHARMS	12.5MG; 80MG	A203000	001	Mar 15, 2019	Mar	NEWA
>A>	AB		12.5MG; 160MG	A203000	002	Mar 15, 2019	Mar	NEWA
>A>	AB		12.5MG; 320MG	A203000	003	Mar 15, 2019	Mar	NEWA
>A>	AB		25MG; 160MG	A203000	004	Mar 15, 2019	Mar	NEWA
>A>	AB		25MG; 320MG	A203000	005	Mar 15, 2019	Mar	NEWA
	<u>HYDROCODONE BITARTRATE; IBUPROFEN</u>							
	TABLET; ORAL							
	HYDROCODONE BITARTRATE AND IBUPROFEN							
	@ TEVA	7.5MG; 200MG	A076023	001	Apr 11, 2003	Feb	DISC	

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION; ORAL						
	HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	@ TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Feb	DISC
AA		5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Jan	NEWA

HYDROCORTISONE

CREAM; TOPICAL

NUTRACORT

	@ BAUSCH	0.5%	A080442	002		Feb	CAHN
	@	1%	A080442	003		Feb	CAHN

LOTION; TOPICAL

CETACORT

	@ BAUSCH	0.5%	A080426	002		Feb	CAHN
	@	1%	A080426	001		Feb	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

>D>	AB	+ SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Mar	DISC
>A>		+ @	8MG	N021217	001	Mar 01, 2010	Mar	DISC
>D>	AB	+	12MG	N021217	002	Mar 01, 2010	Mar	DISC
>A>		+ @	12MG	N021217	002	Mar 01, 2010	Mar	DISC
>D>	AB	+	16MG	N021217	003	Mar 01, 2010	Mar	DISC
>A>		+ @	16MG	N021217	003	Mar 01, 2010	Mar	DISC
>D>	AB	+!	32MG	N021217	004	Aug 24, 2012	Mar	DISC
>A>		+ @	32MG	N021217	004	Aug 24, 2012	Mar	DISC

HYDROMORPHONE HYDROCHLORIDE

>D>	AB	OSMOTICA	32MG	A205629	004	Jul 07, 2016	Mar	CHRS
>A>	AB	!	32MG	A205629	004	Jul 07, 2016	Mar	CHRS

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Jan	CAHN
	@ LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Feb	DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

>A>	AP	SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019	Mar	NEWA
>A>	AP	SUN PHARM	1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Mar	NEWA

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

	+!	VALEANT PHARMS INTL	5MG	N018771	001		Jan	CAHN
--	----	---------------------	-----	---------	-----	--	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

>D>		@ LUITPOLD	50MG/ML	A087408	002		Mar	CMFD
>A>		!	50MG/ML	A087408	002		Mar	CMFD
		@	50MG/ML	A087408	002		Feb	DISC

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	TORRENT	10MG/5ML	A210634	001	Feb 26, 2019	Feb	NEWA
----	---------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	10MG	A040604	002	Dec 28, 2004	Jan	CAHN
AB		25MG	A040604	003	Dec 28, 2004	Jan	CAHN
AB		50MG	A040604	001	Dec 28, 2004	Jan	CAHN
AB	KVK TECH	25MG	A040786	002	Mar 20, 2007	Feb	CMS1
AB		50MG	A040786	003	Mar 20, 2007	Feb	CMS1

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

@	BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991	Feb	CAHN
---	--------------------	-----------------------	---------	-----	--------------	-----	------

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+	CUMBERLAND PHARMS	800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019	Jan	NEWA
---	-------------------	----------------------	---------	-----	--------------	-----	------

TABLET;ORAL

IBUPROFEN

>D>	AB	HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar	DISC
>A>		@	400MG	A204062	001	Sep 10, 2018	Mar	DISC
>D>	AB		600MG	A204062	002	Sep 10, 2018	Mar	DISC
>A>		@	600MG	A204062	002	Sep 10, 2018	Mar	DISC
>D>	AB		800MG	A204062	003	Sep 10, 2018	Mar	DISC
>A>		@	800MG	A204062	003	Sep 10, 2018	Mar	DISC

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@	LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010	Feb	DISC
---	----------	----------	---------	-----	--------------	-----	------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb	NEWA
AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb	NEWA
AB	BRECKENRIDGE PHARM	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb	NEWA
AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb	NEWA
AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb	NEWA
AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb	NEWA
AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan	NEWA
AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan	NEWA
AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan	NEWA
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

>D>		OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar	DISC
>A>		@	10MG	A040751	003	Feb 28, 2008	Mar	DISC
>D>			25MG	A040751	002	Feb 28, 2008	Mar	DISC
>A>		@	25MG	A040751	002	Feb 28, 2008	Mar	DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN
---	--------	------------	---------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN
---	--------	---------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

+	@	EGALET	25MG	N016059	001		Feb	CAHN
+	@		50MG	N016059	002		Feb	CAHN

INDOMETHACIN

AB	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb	CAHN
AB		50MG	A070756	001	Feb 12, 1986	Feb	CAHN

TIVORBEX

+	EGALET	20MG	N204768	001	Feb 24, 2014	Feb	CAHN
+	!	40MG	N204768	002	Feb 24, 2014	Feb	CAHN

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+	@	EGALET	75MG	N018185	001	Feb 23, 1982	Feb	CAHN
---	---	--------	------	---------	-----	--------------	-----	------



SUPPOSITORY;RECTAL  
INDOCIN

+ @	EGALET	50MG	N017814	001	Aug 13, 1984	Feb	CAHN
SUSPENSION;ORAL							
INDOCIN							
+!	EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb	CAHN

IOPROMIDE

INJECTABLE;INJECTION  
ULTRAVIST (PHARMACY BULK)

+ @	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004	Feb	DISC
ULTRAVIST 240							
+ @	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995	Feb	DISC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL  
IPRATROPIUM BROMIDE

>D>	AB	MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Mar	DISC
>A>		@	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Mar	DISC
>D>	AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	Mar	DISC
>A>		@	0.042MG/SPRAY	A075553	001	Mar 31, 2003	Mar	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
IRINOTECAN HYDROCHLORIDE

AP	FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Jan	CAHN
AP		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Jan	CAHN

IRON DEXTRAN

INJECTABLE;INJECTION  
DEXFERRUM

>D>	BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar	DISC
>A>		@	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar	DISC
>D>		PROFERDEX						
>D>	BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001		Mar	DISC
>A>		@	EQ 50MG IRON/ML	N017807	001		Mar	DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION  
ISUPREL

>A>	AP	+!	BAUSCH	0.2MG/ML	N010515	001		Mar	CAHN
>D>	AP	+!	VALEANT PHARMS NORTH	0.2MG/ML	N010515	001		Mar	CAHN

ISOSORBIDE DINITRATE

TABLET;ORAL  
ISORDIL

>A>	AB	+	BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar	CAHN
>A>		+	@	10MG	N012093	002	Jul 29, 1988	Mar	CAHN
>A>		+	@	20MG	N012093	006	Jul 29, 1988	Mar	CAHN
>A>		+	@	30MG	N012093	005	Jul 29, 1988	Mar	CAHN
>A>		+	!	40MG	N012093	001	Jul 29, 1988	Mar	CAHN
>D>	AB	+	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Mar	CAHN
>D>		+	@	10MG	N012093	002	Jul 29, 1988	Mar	CAHN
>D>		+	@	20MG	N012093	006	Jul 29, 1988	Mar	CAHN
>D>		+	@	30MG	N012093	005	Jul 29, 1988	Mar	CAHN
>D>		+	!	40MG	N012093	001	Jul 29, 1988	Mar	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL  
ISOSORBIDE MONONITRATE

>A>	AB		HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar	CAHN
>A>	AB			60MG	A076813	001	Jan 07, 2005	Mar	CAHN
>D>	AB		HIKMA PHARMS	30MG	A076813	002	Mar 30, 2006	Mar	CAHN
>D>	AB			60MG	A076813	001	Jan 07, 2005	Mar	CAHN

KETOCONAZOLE

GEL;TOPICAL  
XOLEGEL

+!	ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb	CAHN
----	----------	----	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb	CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb	CMFD

SOLUTION/DROPS; OPHTHALMIC

KETOROLAC TROMETHAMINE

>A>	AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar	NEWA
-----	----	----------------------	------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb	CAHN	
AB		200MG	A074787	002	Aug 03, 1998	Feb	CAHN	
AB		300MG	A074787	003	Aug 03, 1998	Feb	CAHN	
AB	INVATECH PHARMA	100MG	A207863	001	Feb 04, 2019	Jan	NEWA	
AB		200MG	A207863	002	Feb 04, 2019	Jan	NEWA	
AB		300MG	A207863	003	Feb 04, 2019	Jan	NEWA	
TRANDATE								
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan	CRLD	
AB	+	200MG	N018716	002	Aug 01, 1984	Jan	CRLD	
AB	+	300MG	N018716	003	Aug 01, 1984	Jan	CRLD	

LACTULOSE

SOLUTION; ORAL

LACTULOSE

>D>	@	BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN
	@		10GM/15ML	A075911	001	Feb 21, 2002	Jan	CAHN
AA		TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jan	CAHN
>A>	@	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN

SOLUTION; ORAL, RECTAL

LACTULOSE

	@	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan	CAHN
AA		TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jan	CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

>A>	AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar	NEWA
	AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb	NEWA
	AB		300MG	A078545	002	Mar 05, 2019	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

	@	MYLAN PHARMS INC	150MG;300MG	A204005	001	Aug 28, 2014	Jan	DISC
--	---	------------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

>D>	@	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Mar	CAHN
>D>	@		50MG	A202887	002	Jun 17, 2013	Mar	CAHN
>D>	AB		100MG	A202887	003	Jun 17, 2013	Mar	CAHN
>D>	AB		200MG	A202887	004	Jun 17, 2013	Mar	CAHN
>A>	@	RUBICON	25MG	A202887	001	Jun 17, 2013	Mar	CAHN
>A>	@		50MG	A202887	002	Jun 17, 2013	Mar	CAHN
>A>	AB		100MG	A202887	003	Jun 17, 2013	Mar	CAHN
>A>	AB		200MG	A202887	004	Jun 17, 2013	Mar	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan	NEWA	
AB		30MG	A207394	002	Jan 18, 2019	Jan	NEWA	
	@	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb	DISC
	@		30MG	A091212	002	Sep 16, 2013	Feb	DISC

LAROTRECTINIB

CAPSULE;ORAL

VITRAKVI

	+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
	+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION;ORAL

VITRAKVI

	+	!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
--	---	---	------------------	---------	---------	-----	--------------	----------

>A> LATANOPROST; NETARSUDIL DIMESYLATE

&gt;A&gt; SOLUTION/DROPS;OPHTHALMIC

&gt;A&gt; ROCKLATAN

>A>		+	!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
-----	--	---	---	------------------	----------------------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL

LETROZOLE

AB				FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Feb CAHN
----	--	--	--	--------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP				INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT
----	--	--	--	--------------------	-----------------	---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

>D>									
>D>	AP			LUITPOLD	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Mar DISC
>A>				@	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Mar DISC

LEVOCARNITINE

TABLET;ORAL

LEVOCARNITINE

AB				RISING PHARMS	330MG	A076858	001	Sep 20, 2004	Feb CAHN
----	--	--	--	---------------	-------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE HYDROCHLORIDE

>A>	AA			HETERO LABS LTD III	2.5MG/5ML	A210914	001	Apr 01, 2019	Mar NEWA
-----	----	--	--	---------------------	-----------	---------	-----	--------------	----------

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5%

						A205600	001	Feb 27, 2019	Feb NEWA
--	--	--	--	--	--	---------	-----	--------------	----------

TABLET;ORAL

LEVOFLOXACIN

AB				HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan NEWA
AB					500MG	A204968	002	Feb 05, 2019	Jan NEWA
AB					750MG	A204968	003	Feb 05, 2019	Jan NEWA

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

>A>				+	!	ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018	Mar CAHN
>A>				+	!		300MG/VIAL	N211226	002	Oct 19, 2018	Mar CAHN
>D>				+	!	SPECTRUM PHARMS	175MG/VIAL	N211226	001	Oct 19, 2018	Mar CAHN
>D>				+	!		300MG/VIAL	N211226	002	Oct 19, 2018	Mar CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

>A>	AP			+	!	ACROTECH	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar CAHN
>D>	AP			+	!	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar CAHN

SOLUTION;INTRAVENOUS

FUSILEV

>A>				+	@	ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar CAHN
>A>				+	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar CAHN
>D>				+	@	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar CAHN

SOLUTION;INTRAVENOUS  
FUSILEV

>D>	+	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar CAHN
-----	---	---	---	---------	-----	--------------	----------

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
FETZIMA

AB	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CFTG
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CFTG
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CFTG
AB	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CFTG

## LEVOMILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan NFTG
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan NFTG
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan NFTG
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan NFTG

LEVORPHANOL TARTRATE

## TABLET;ORAL

## LEVORPHANOL TARTRATE

@	SENTYNL THERAPS INC	1MG
@		3MG

A074278	002	Jun 18, 2018	Feb DISC
A074278	003	Jun 18, 2018	Feb DISC

LEVOTHYROXINE SODIUM

## SOLUTION;ORAL

## TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan CMFD
+		25MCG/ML	N206977	002	Dec 15, 2016	Jan CMFD
+		50MCG/ML	N206977	003	Dec 15, 2016	Jan CMFD
+		75MCG/ML	N206977	004	Dec 15, 2016	Jan CMFD
+		88MCG/ML	N206977	005	Dec 15, 2016	Jan CMFD
+		100MCG/ML	N206977	006	Dec 15, 2016	Jan CMFD
+		112MCG/ML	N206977	007	Dec 15, 2016	Jan CMFD
+		125MCG/ML	N206977	008	Dec 15, 2016	Jan CMFD
+		137MCG/ML	N206977	009	Dec 15, 2016	Jan CMFD
+		150MCG/ML	N206977	010	Dec 15, 2016	Jan CMFD
+		175MCG/ML	N206977	011	Dec 15, 2016	Jan CMFD
+	!	200MCG/ML	N206977	012	Dec 15, 2016	Jan CMFD

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

## LEVOTHYROXINE SODIUM

AB1, AB2	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Feb NEWA
AB1, AB2		0.05MG	A210831	002	Feb 19, 2019	Feb NEWA
AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb NEWA
AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb NEWA
AB1, AB2		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA
AB1, AB2		0.15MG	A210831	009	Feb 19, 2019	Feb NEWA
AB1, AB2		0.175MG	A210831	010	Feb 19, 2019	Feb NEWA
AB1, AB2		0.2MG	A210831	011	Feb 19, 2019	Feb NEWA
AB1, AB2		0.3MG	A210831	012	Feb 19, 2019	Feb NEWA
AB2	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Jan NEWA
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan NEWA
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan NEWA
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan NEWA
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan NEWA
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan NEWA
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan NEWA
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan NEWA

TABLET;ORAL  
LEVOTHYROXINE SODIUM

AB2		0.15MG	A209713	009	Jan 18, 2019	Jan	NEWA
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan	NEWA
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan	NEWA
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan	NEWA
THYRO-TABS							
>A>	AB2, + AB4	ALVOGEN 0.025MG	N021116	001	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.05MG	N021116	002	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.075MG	N021116	003	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.088MG	N021116	010	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.1MG	N021116	004	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.112MG	N021116	011	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.125MG	N021116	005	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.137MG	N021116	012	Dec 07, 2004	Mar	CAHN
>A>	AB2, + AB4	0.15MG	N021116	006	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.175MG	N021116	007	Oct 24, 2002	Mar	CAHN
>A>	AB2, + AB4	0.2MG	N021116	008	Oct 24, 2002	Mar	CAHN
>A>	AB2, +! AB4	0.3MG	N021116	009	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	LLOYD 0.025MG	N021116	001	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.025MG	N021116	001	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.05MG	N021116	002	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.05MG	N021116	002	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.075MG	N021116	003	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.075MG	N021116	003	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.088MG	N021116	010	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.088MG	N021116	010	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.1MG	N021116	004	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.1MG	N021116	004	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.112MG	N021116	011	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.112MG	N021116	011	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.125MG	N021116	005	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.125MG	N021116	005	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.137MG	N021116	012	Dec 07, 2004	Mar	CAHN
>D>	AB2, + AB4	0.137MG	N021116	012	Dec 07, 2004	Feb	CMFD
>D>	AB2, + AB4	0.15MG	N021116	006	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.15MG	N021116	006	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.175MG	N021116	007	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.175MG	N021116	007	Oct 24, 2002	Feb	CMFD
>D>	AB2, + AB4	0.2MG	N021116	008	Oct 24, 2002	Mar	CAHN
>D>	AB2, + AB4	0.2MG	N021116	008	Oct 24, 2002	Feb	CMFD
>D>	AB2, +! AB4	0.3MG	N021116	009	Oct 24, 2002	Mar	CAHN
>D>	AB2, +! AB4	0.3MG	N021116	009	Oct 24, 2002	Feb	CMFD

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE

>D>	AP	LUITPOLD	1%	A080850	001		Mar	DISC
>A>		@	1%	A080850	001		Mar	DISC
		@	1%	A091564	001	Aug 14, 2015	Feb	DISC

LIOETHYRONINE SODIUMTABLET; ORAL  
LIOETHYRONINE SODIUM

>D>	AB	MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC
>A>		@	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC
>D>	AB		EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC
>A>		@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC
>D>	AB		EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC
>A>		@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC

LISINOPRILTABLET; ORAL  
LISINOPRIL

AB		HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
AB			5MG	A075752	002	Jul 01, 2002	Feb	CAHN
AB			10MG	A075752	003	Jul 01, 2002	Feb	CAHN
AB			20MG	A075752	004	Jul 01, 2002	Feb	CAHN
AB			30MG	A075752	005	Jul 01, 2002	Feb	CAHN
AB			40MG	A075752	006	Jul 01, 2002	Feb	CAHN

LORAZEPAMCONCENTRATE; ORAL  
LORAZEPAM

AA		SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Feb	CAHN
----	--	-----------------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
ATIVAN

>A>	AP	+	HIKMA	2MG/ML	N018140	001	Mar	CAHN
>A>	AP	+		4MG/ML	N018140	002	Mar	CAHN
>D>	AP	+	WEST-WARD PHARMS INT	2MG/ML	N018140	001	Mar	CAHN
>D>	AP	+		4MG/ML	N018140	002	Mar	CAHN

TABLET; ORAL  
ATIVAN

AB	+	BAUSCH	0.5MG	N017794	001		Feb	CAHN
AB	+		1MG	N017794	002		Feb	CAHN
AB	+		2MG	N017794	003		Feb	CAHN

LOSARTAN POTASSIUMTABLET; ORAL  
LOSARTAN POTASSIUM

>A>	AB	HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019	Mar	NEWA
>A>	AB		50MG	A204795	002	Apr 04, 2019	Mar	NEWA
>A>	AB		100MG	A204795	003	Apr 04, 2019	Mar	NEWA
>A>	AB	MICRO LABS	25MG	A091541	001	Sep 24, 2012	Mar	CAHN
>A>	AB		50MG	A091541	002	Sep 24, 2012	Mar	CAHN
>A>	AB		100MG	A091541	003	Sep 24, 2012	Mar	CAHN
>D>	AB	VIVA HLTHCARE	25MG	A091541	001	Sep 24, 2012	Mar	CAHN
>D>	AB		50MG	A091541	002	Sep 24, 2012	Mar	CAHN
>D>	AB		100MG	A091541	003	Sep 24, 2012	Mar	CAHN

LOTEPREDNOL ETABONATEGEL; OPHTHALMIC  
LOTEMAX SM

+	!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Feb	NEWA
---	---	---------------------	-------	---------	-----	--------------	-----	------

LOVASTATINTABLET; ORAL  
LOVASTATIN

AB		BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb	CAHN
AB			20MG	A075300	002	Dec 17, 2001	Feb	CAHN
AB			40MG	A075300	003	Dec 17, 2001	Feb	CAHN
		@ MYLAN	10MG	A075451	001	Dec 17, 2001	Feb	DISC
		@	20MG	A075451	002	Dec 17, 2001	Feb	DISC
		@	40MG	A075451	003	Dec 17, 2001	Feb	DISC

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

@	TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001		Feb	CAHN
---	--------------------	-----------------	---------	-----	--	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

+	@	TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb	CAHN
+	@		EQ 5MG BASE	N017525	001		Feb	CAHN
+	@		EQ 10MG BASE	N017525	002		Feb	CAHN
+	@		EQ 10MG BASE	N017525	002		Feb	CAHN
+	@		EQ 25MG BASE	N017525	003		Feb	CAHN
+	@		EQ 25MG BASE	N017525	003		Feb	CAHN
+	@		EQ 50MG BASE	N017525	004		Feb	CAHN
+	@		EQ 50MG BASE	N017525	004		Feb	CAHN

TABLET; ORAL

LOXITANE

+	@	TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb	CAHN
+	@		EQ 10MG BASE	N017525	006		Feb	CAHN
+	@		EQ 25MG BASE	N017525	007		Feb	CAHN
+	@		EQ 25MG BASE	N017525	007		Feb	CAHN
+	@		EQ 50MG BASE	N017525	008		Feb	CAHN
+	@		EQ 50MG BASE	N017525	008		Feb	CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

	@	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	DISC
	@		40MG	A208055	002	Jan 03, 2019	Feb	DISC
	@		80MG	A208055	003	Jan 03, 2019	Feb	DISC
	@		120MG	A208055	004	Jan 03, 2019	Feb	DISC
>A>	AB	ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Mar	NEWA
>A>	AB		40MG	A208052	002	Mar 19, 2019	Mar	NEWA
>A>	AB		60MG	A208052	003	Mar 19, 2019	Mar	NEWA
>A>	AB		80MG	A208052	004	Mar 19, 2019	Mar	NEWA
>A>	AB		120MG	A208052	005	Mar 19, 2019	Mar	NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan	CTEC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

>D>		POWDER; ORAL						
>D>		COLPREP KIT						
>D>	+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553	001	Dec 27, 2016	Mar	DISC
>A>	+	@	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553	001	Dec 27, 2016	Mar	DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

>D>	AP	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar	DISC
>A>		@	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar	DISC

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb	CMFD
	+	@	12.5MG	N010721	006		Jan	CRLD
AA	+		25MG	N010721	004		Feb	CMFD
	+	@	25MG	N010721	004		Jan	CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb	CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan	CRLD

MECLIZINE HYDROCHLORIDE

AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan	CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan	CHRS
AA		INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb	NEWA
AA			25MG	A205136	002	Feb 22, 2019	Feb	NEWA
			50MG	A205136	003	Feb 22, 2019	Feb	NEWA

	TABLET, CHEWABLE;ORAL						
	ANTIVERT						
AA	+ CASPER PHARMA LLC	25MG	N010721	005			Feb CMFD
	+ @	25MG	N010721	005			Jan CRLD
	<u>MEDROXYPROGESTERONE ACETATE</u>						
	INJECTABLE; INJECTION						
	MEDROXYPROGESTERONE ACETATE						
AB	CIPLA	150MG/ML	A210335	001	Jan 25, 2019		Jan NEWA
	<u>MEFENAMIC ACID</u>						
	CAPSULE;ORAL						
	MEFENAMIC ACID						
	@ BRECKENRIDGE PHARM	250MG	A090359	001	Feb 05, 2013		Feb DISC
	<u>MELOXICAM</u>						
	CAPSULE;ORAL						
	VIVLODEX						
	+ EGALET	5MG	N207233	001	Oct 22, 2015		Feb CAHN
	+!	10MG	N207233	002	Oct 22, 2015		Feb CAHN
	TABLET;ORAL						
	MELOXICAM						
AB	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006		Feb CAHN
AB		15MG	A077936	002	Jul 19, 2006		Feb CAHN
	<u>MELPHALAN HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	ALKERAN						
AP	+ APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992		Feb CMFD
	POWDER; INTRAVENOUS						
	EVOMELA						
>A>	+! ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016		Mar CAHN
>D>	+! SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016		Mar CAHN
	<u>MEMANTINE HYDROCHLORIDE</u>						
	SOLUTION;ORAL						
	MEMANTINE HYDROCHLORIDE						
AA	! TORRENT	2MG/ML	A205446	001	Dec 07, 2015		Jan CAHN
	TABLET;ORAL						
	MEMANTINE HYDROCHLORIDE						
	@ APOTEX INC	5MG	A090244	001	Jul 11, 2018		Jan DISC
	@	10MG	A090244	002	Jul 11, 2018		Jan DISC
	<u>MEQUINOL; TRETINOIN</u>						
	SOLUTION;TOPICAL						
	SOLAGE						
	@ ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999		Feb CAHN
	<u>MESALAMINE</u>						
	TABLET, DELAYED RELEASE;ORAL						
	MESALAMINE						
AB	SUN PHARM	1.2GM	A211858	001	Jan 25, 2019		Jan NEWA
	<u>METAXALONE</u>						
	TABLET;ORAL						
	METAXALONE						
AB	APPCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018		Feb CAHN
	<u>METFORMIN HYDROCHLORIDE</u>						
	TABLET;ORAL						
	METFORMIN HYDROCHLORIDE						
AB	HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002		Feb CAHN
AB		850MG	A075978	002	Jan 25, 2002		Feb CAHN
AB		1GM	A075978	003	Nov 05, 2002		Feb CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	METFORMIN HYDROCHLORIDE						
AB1	CADILA	500MG	A077060	001	Apr 20, 2005		Feb CAHN
AB		750MG	A077078	001	Apr 21, 2005		Feb CAHN
>D>	AB1	YICHANG HUMANWELL	A211052	001	Sep 24, 2018		Mar DISC
>A>	@	500MG	A211052	001	Sep 24, 2018		Mar DISC
>D>	AB	750MG	A211052	002	Sep 24, 2018		Mar DISC



	TABLET, EXTENDED RELEASE;ORAL								
	METFORMIN HYDROCHLORIDE								
>A>	@	750MG		A211052	002	Sep 24, 2018		Mar	DISC
	<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	ACTOPLUS MET XR								
>D>	+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009		Mar	DISC
>A>	+	@	1GM;EQ 15MG BASE	N022024	001	May 12, 2009		Mar	DISC
>D>	+	!	1GM;EQ 30MG BASE	N022024	002	May 12, 2009		Mar	DISC
>A>	+	@	1GM;EQ 30MG BASE	N022024	002	May 12, 2009		Mar	DISC
	<u>METHAZOLAMIDE</u>								
	TABLET;ORAL								
	METHAZOLAMIDE								
>D>	AB	MICRO LABS	25MG	A207438	001	Oct 05, 2018		Mar	DISC
>A>		@	25MG	A207438	001	Oct 05, 2018		Mar	DISC
>D>	AB		50MG	A207438	002	Oct 05, 2018		Mar	DISC
>A>		@	50MG	A207438	002	Oct 05, 2018		Mar	DISC
	<u>METHOCARBAMOL</u>								
	SOLUTION; IM-IV								
	METHOCARBAMOL								
AP		SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017		Feb	CAHN
		ROBAXIN							
AP	+	!	HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb	CAHN
	<u>METHYLDOPA</u>								
	TABLET;ORAL								
	METHYLDOPA								
AB		HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986		Feb	CAHN
AB			500MG	A070343	001	Feb 20, 1986		Feb	CAHN
	<u>METHYLDOPATE HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	METHYLDOPATE HYDROCHLORIDE								
>D>	!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987		Mar	DISC
>A>		@	50MG/ML	A071279	001	Oct 02, 1987		Mar	DISC
	<u>METHYLERGONOVINE MALEATE</u>								
	TABLET;ORAL								
	METHYLERGONOVINE MALEATE								
>A>	AB	TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019		Mar	NEWA
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	ADHANSIA XR								
>D>		PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019		Mar	CRLD
>A>	+		25MG	N212038	001	Feb 27, 2019		Mar	CRLD
			25MG	N212038	001	Feb 27, 2019		Feb	NEWA
	+		35MG	N212038	002	Feb 27, 2019		Feb	NEWA
	+		45MG	N212038	003	Feb 27, 2019		Feb	NEWA
	+		55MG	N212038	004	Feb 27, 2019		Feb	NEWA
	+		70MG	N212038	005	Feb 27, 2019		Feb	NEWA
	+		85MG	N212038	006	Feb 27, 2019		Feb	NEWA
	FOR SUSPENSION, EXTENDED RELEASE;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
	@	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018		Jan	DISC
		QUILLIVANT XR							
	+	!	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb	CAHN
	+	!	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan	CTEC
	TABLET;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
AB		CEDIPROF INC	5MG	A208737	001	Feb 01, 2019		Jan	NEWA
AB			10MG	A208737	002	Feb 01, 2019		Jan	NEWA
AB			20MG	A208737	003	Feb 01, 2019		Jan	NEWA
	@	LANNETT CO INC	5MG	A086429	001			Jan	DISC
	@		10MG	A085799	001			Jan	DISC
	@		20MG	A086428	001			Jan	DISC

## TABLET, EXTENDED RELEASE;ORAL

	METADATE ER							
	@ LANNETT CO INC	20MG	A089601	001	Jun 01, 1988	Jan	DISC	
	METHYLPHENIDATE HYDROCHLORIDE							
AB	! ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan	NEWA	

METHYLPREDNISOLONE

## TABLET;ORAL

## MEDROL

>D>	+	PHARMACIA AND UPJOHN	2MG	N011153	002			Mar	CFTG
>A>	AB	+	2MG	N011153	002			Mar	CFTG
		METHYLPREDNISOLONE							
>D>	AB	LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Mar	NFTG	
>A>	AB		2MG	A209097	001	Feb 22, 2019	Mar	NFTG	
	AB		2MG	A209097	001	Feb 22, 2019	Feb	NEWA	
	AB		4MG	A209097	002	Feb 22, 2019	Feb	NEWA	
	AB		8MG	A209097	003	Feb 22, 2019	Feb	NEWA	
	AB		16MG	A209097	004	Feb 22, 2019	Feb	NEWA	
	AB		32MG	A209097	005	Feb 22, 2019	Feb	NEWA	

METHYLPREDNISOLONE SODIUM SUCCINATE

## INJECTABLE;INJECTION

## A-METHAPRED

>D>	AP	HOSPIRA	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005	Mar	DISC	
>A>		@	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005	Mar	DISC	
>D>	AP		EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005	Mar	DISC	
>A>		@	EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005	Mar	DISC	

METOPROLOL SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## TOPROL-XL

>D>	AB	+	ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Mar	CAHN
>D>	AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Mar	CAHN
>D>	AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Mar	CAHN
>D>	AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Mar	CAHN
>A>	AB	+	TOPROL	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Mar	CAHN
>A>	AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Mar	CAHN
>A>	AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Mar	CAHN
>A>	AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Mar	CAHN

METOPROLOL TARTRATE

## INJECTABLE;INJECTION

## METOPROLOL TARTRATE

>D>	AP	LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009	Mar	DISC	
>A>		@	1MG/ML	A090386	001	Sep 30, 2009	Mar	DISC	
		@	1MG/ML	A091307	001	Dec 29, 2010	Feb	DISC	

METRONIDAZOLE

## GEL;VAGINAL

## METROGEL-VAGINAL

>A>	AB	+	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar	CAHN
>D>	AB	+	MEDICIS	0.75%	N020208	001	Aug 17, 1992	Mar	CAHN

## INJECTABLE;INJECTION

## METRONIDAZOLE IN PLASTIC CONTAINER

AP		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb	NEWA	
----	--	-----------	-------------	---------	-----	--------------	-----	------	--

## TABLET;ORAL

## METRONIDAZOLE

>A>	AB		CADILA	250MG	A206560	001	Nov 16, 2016	Mar	CAHN
>A>	AB			500MG	A206560	002	Nov 16, 2016	Mar	CAHN
>D>	AB		ZYDUS PHARMS	250MG	A206560	001	Nov 16, 2016	Mar	CAHN
>D>	AB			500MG	A206560	002	Nov 16, 2016	Mar	CAHN

METYROSINE

## CAPSULE;ORAL

## DEMSEER

>D>		+	ATON PHARMA VPNA	250MG	N017871	001		Mar	CAHN
>A>		+	BAUSCH	250MG	N017871	001		Mar	CAHN

MIFEPRISTONETABLET; ORAL  
MIFEPREX

>D>	+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar	CFTG
>A>	AB	+	200MG	N020687	001	Sep 28, 2000	Mar	CFTG
>A>		MIFEPRISTONE						
>A>	AB	GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar	NFTG

MILRINONE LACTATEINJECTABLE; INJECTION  
MILRINONE LACTATE

@	GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006	Feb	DISC
---	------------------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
MINOCYCLINE HYDROCHLORIDE

AB	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan	CMFD
AB		EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan	CMFD

MITOMYCININJECTABLE; INJECTION  
MITOMYCIN

AP	WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CMFD
AP		40MG/VIAL	A064117	003	Jun 02, 1999	Jan	CMFD

MITOXANTRONE HYDROCHLORIDEINJECTABLE; INJECTION  
MITOXANTRONE HYDROCHLORIDE

>D>	AP	MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar	DISC
>A>		@	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar	DISC
>D>	AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar	DISC
>A>		@	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar	DISC

MONTELUKAST SODIUMGRANULE; ORAL  
MONTELUKAST SODIUM

>A>	AB	MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb	DISC
>D>	AB	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar	CAHN
>D>	AB	TORRENT PHARMS LLC	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar	CAHN

TABLET; ORAL

MONTELUKAST SODIUM

@	VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb	DISC
---	--------------------	--------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

@	VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb	DISC
@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb	DISC

MORPHINE SULFATEINJECTABLE; INJECTION  
ASTRAMORPH PF

>D>	AP	FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar	DISC
>A>		@	0.5MG/ML	A071050	001	Oct 07, 1986	Mar	DISC
>D>	AP		0.5MG/ML	A071051	001	Oct 07, 1986	Mar	DISC
>A>		@	0.5MG/ML	A071051	001	Oct 07, 1986	Mar	DISC
>D>	AP		1MG/ML	A071052	001	Oct 07, 1986	Mar	DISC
>A>		@	1MG/ML	A071052	001	Oct 07, 1986	Mar	DISC
>D>	AP		1MG/ML	A071053	001	Oct 07, 1986	Mar	DISC
>A>		@	1MG/ML	A071053	001	Oct 07, 1986	Mar	DISC

SOLUTION; ORAL

MORPHINE SULFATE

@	LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb	DISC
@		20MG/5ML	A202310	001	Oct 30, 2015	Jan	DISC
@		100MG/5ML	N201517	001	Jun 23, 2011	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

ARYMO ER

>D>	+	@	EGALET	15MG	N208603	001	Jan 09, 2017	Mar	CAHN
>A>		+	@	15MG	N208603	001	Jan 09, 2017	Mar	CAHN
>D>		+	@	30MG	N208603	002	Jan 09, 2017	Mar	CAHN
>A>		+	@	30MG	N208603	002	Jan 09, 2017	Mar	CAHN
>D>		+	@	60MG	N208603	003	Jan 09, 2017	Mar	CAHN
>A>		+	@	60MG	N208603	003	Jan 09, 2017	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

@ MYLAN PHARMS INC 200MG

A200824 005 Oct 18, 2011 Feb DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1 ALEMBIC PHARMS LTD EQ 0.5% BASE

A209469 001 Feb 13, 2019 Jan NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

&gt;D&gt; AB SUNSHINE LAKE EQ 400MG BASE

A206295 001 Sep 28, 2018 Mar DISC

&gt;A&gt; @ EQ 400MG BASE

A206295 001 Sep 28, 2018 Mar DISC

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB VISTAPHARM 200MG/ML

A210370 001 Feb 12, 2019 Jan NEWA

NAFTIFINE HYDROCHLORIDE

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

&gt;A&gt; AB TARO 2%

A208201 001 Apr 10, 2019 Mar NFTG

&gt;A&gt; AB TOLMAR 1%

A206165 001 Mar 20, 2019 Mar NFTG

NAFTIN

&gt;D&gt; +! SEBELA IRELAND LTD 1%

N019356 001 Jun 18, 1990 Mar CFTG

&gt;A&gt; AB +! 1%

N019356 001 Jun 18, 1990 Mar CFTG

&gt;D&gt; +! 2%

N204286 001 Jun 27, 2013 Mar CFTG

&gt;A&gt; AB +! 2%

N204286 001 Jun 27, 2013 Mar CFTG

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

AP MYLAN LABS LTD 10MG/ML

A206506 001 Feb 06, 2019 Jan NEWA

AP 20MG/ML

A206506 002 Feb 06, 2019 Jan NEWA

NALOXONE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO (AUTOINJECTOR)

+! KALEO INC 2MG/0.4ML (2MG/0.4ML)

N209862 001 Oct 19, 2016 Feb CTNA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB LUPIN EQ 0.5MG BASE;EQ 50MG BASE

A075735 001 Jul 11, 2001 Feb CAHN

NANDROLONE DECANOATE

INJECTABLE;INJECTION

NANDROLONE DECANOATE

@ LUITPOLD 200MG/ML

A091252 001 Aug 30, 2010 Feb DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP AMRING PHARMS 5MG/10ML (0.5MG/ML)

A210989 001 Aug 22, 2018 Jan CAHN

AP 10MG/10ML (1MG/ML)

A210989 002 Aug 22, 2018 Jan CAHN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB MYLAN PHARMS INC 500MG

A203742 001 Feb 22, 2019 Feb NEWA

AB 750MG

A203742 002 Feb 22, 2019 Feb NEWA

AB 1GM

A203742 003 Feb 22, 2019 Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2 NOVAST LABS 30MG

A210614 001 Mar 12, 2019 Feb NEWA

AB2 60MG

A210614 002 Mar 12, 2019 Feb NEWA

AB2 90MG

A210614 003 Mar 12, 2019 Feb NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
NITROGLYCERIN

AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb	NEWA
AB2	! MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb	CTEC

NORETHINDRONE

TABLET;ORAL-28  
MICRONOR

>D>	AB2	+! JANSSEN PHARMS	0.35MG	N016954	001		Mar	DISC
>A>		+ @	0.35MG	N016954	001		Mar	DISC
		NORETHINDRONE						
>D>	AB2	MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar	CHRS
>A>	AB2	!	0.35MG	A200980	001	Jun 12, 2013	Mar	CHRS

NYSTATIN

OINTMENT;TOPICAL  
NYSTATIN

AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan	NEWA
		POWDER;TOPICAL NYSTATIN					
AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A>	@ ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	DISC	
>D>	AT	ZYDUS PHARMS USA INC	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	DISC

OCTREOTIDE ACETATE

INJECTABLE;INJECTION  
OCTREOTIDE ACETATE

>D>	AP	HERITAGE PHARMS INC	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar	DISC
>A>		@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar	DISC
	AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan	CAHN
>D>	AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar	DISC
>A>		@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar	DISC
	AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan	CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb	CMFD	
>D>	AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar	DISC
>A>		@	0.3%	A076231	001	May 14, 2004	Mar	DISC

SOLUTION/DROPS;OTIC  
OFLOXACIN

>D>	AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar	DISC
>A>		@	0.3%	A078222	001	Mar 17, 2008	Mar	DISC

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL  
OLANZAPINE

	@	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb	DISC
	@		10MG	A208146	002	Jul 02, 2018	Feb	DISC
	@		15MG	A208146	003	Jul 02, 2018	Feb	DISC
	@		20MG	A208146	004	Jul 02, 2018	Feb	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL  
OLMESARTAN MEDOXOMIL

AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb	NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb	NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb	NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

>A> AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar	NEWA
--------	----------------------	--------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL  
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb	NEWA
----	-------------------	--	---------	-----	--------------	-----	------

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

	@ LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb	DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	@ HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb	DISC
	@ LUITPOLD	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb	DISC

TABLET;ORAL

	ONDANSETRON HYDROCHLORIDE						
	@ MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb	DISC

ORPHENADRINE CITRATEINJECTABLE;INJECTION  
NORFLEX

	+ @ TELIGENT	30MG/ML	N013055	001		Jan	CRLD
--	--------------	---------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

	ORPHENADRINE CITRATE						
AB	LUPIN	100MG	A040284	001	Jun 19, 1998	Feb	CAHN

OSELTAMIVIR PHOSPHATEFOR SUSPENSION;ORAL  
OSELTAMIVIR PHOSPHATE

AB	TEVA PHARMS USA	EQ 6MG BASE/ML	A211125	001	Feb 27, 2019	Feb	NEWA
----	-----------------	----------------	---------	-----	--------------	-----	------

OXALIPLATININJECTABLE;INTRAVENOUS  
ELOXATIN

	+ @ SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002	Feb	CDFR
AP	+	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Feb	CDFR
	+ @	100MG/VIAL	N021492	002	Aug 09, 2002	Feb	CDFR
AP	+	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Feb	CDFR
	+ @	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Feb	CDFR

OXALIPLATIN

AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Feb	CDFR
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Feb	CDFR
AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	CDFR
AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Feb	CDFR
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Feb	CDFR
AP	CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb	CDFR
AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb	CDFR
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb	CDFR
AP		50MG/VIAL	A078819	001	Jun 02, 2010	Feb	CDFR
AP		50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb	CDFR
AP		100MG/VIAL	A078819	002	Jun 02, 2010	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb	CDFR
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb	CDFR
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb	CDFR
AP		50MG/VIAL	A207385	001	May 23, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb	CDFR
AP		100MG/VIAL	A207385	002	May 23, 2017	Feb	CDFR
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb	CDFR
AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb	CDFR
AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb	CDFR

INJECTABLE; INTRAVENOUSOXALIPLATIN

AP		JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb CDFR
AP			100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb CDFR
	@	LUITPOLD	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	Feb DISC
AP			50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	Feb CDFR
	@		100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	Feb DISC
AP			100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	Feb CDFR
AP		MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb CDFR
AP			50MG/VIAL	A200979	001	Aug 08, 2012	Feb CDFR
AP			100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb CDFR
AP			100MG/VIAL	A200979	002	Aug 08, 2012	Feb CDFR
AP			200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb CDFR
AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR
AP			50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP			100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP		SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@		50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP			100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@		100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR

OXAPROZIN

## TABLET; ORAL

OXAPROZIN

>A>	@	BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar CAHN
>D>	@	SANDOZ	600MG	A075842	001	Apr 12, 2001	Mar CAHN

OXYBUTYNIN CHLORIDE

## TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB		INVATECH PHARMA	5MG	A211062	001	Feb 06, 2019	Jan NEWA
			TABLET, EXTENDED RELEASE; ORAL				
			<u>OXYBUTYNIN CHLORIDE</u>				
AB		AJANTA PHARMA LTD	5MG	A211655	001	Feb 28, 2019	Feb NEWA
AB			10MG	A211655	002	Feb 28, 2019	Feb NEWA
AB			15MG	A211655	003	Feb 28, 2019	Feb NEWA

OXYCODONE HYDROCHLORIDE

## SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA		ALKEM LABS LTD	5MG/5ML	A211748	001	Feb 07, 2019	Feb NEWA
AA			100MG/5ML	A211749	001	Feb 04, 2019	Jan NEWA
	@	LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014	Jan DISC
AA		PHARM ASSOC	5MG/ML	A206914	001	Feb 01, 2019	Jan NEWA

PACLITAXEL

## INJECTABLE; INJECTION

PACLITAXEL

>D>	AP	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Mar DISC
>A>	@		6MG/ML	A205720	001	Aug 17, 2018	Mar DISC

PALONOSETRON HYDROCHLORIDE

## INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>D>	AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar DISC
>A>	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar DISC

PAMIDRONATE DISODIUM

## INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D>	AP	LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar DISC
>A>	@		30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar DISC
>D>	AP		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar DISC
>A>	@		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar DISC
	@	SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008	Jan DISC

INJECTABLE; INJECTION  
PAMIDRONATE DISODIUM  
@

90MG/VIAL

A077703 002 Dec 24, 2008 Jan DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL  
PANTOPRAZOLE SODIUM

AB INGENUS PHARMS LLC EQ 40MG BASE

A211368 001 Mar 01, 2019 Feb NEWA

PENICILLAMINE

CAPSULE; ORAL  
CUPRIMINE

@ VALEANT PHARMS INTL 125MG  
+! 250MG

N019853 002 Jan CAHN  
N019853 001 Jan CAHN

PENTOSTATIN

INJECTABLE; INJECTION  
PENTOSTATIN

>D> AP MYLAN INSTITUTIONAL 10MG/VIAL  
>A> @ 10MG/VIAL

A203554 001 Sep 19, 2014 Mar DISC  
A203554 001 Sep 19, 2014 Mar DISC

PERMETHRIN

CREAM; TOPICAL  
PERMETHRIN

&gt;A&gt; AB ENCUBE ETHICALS 5%

A211303 001 Apr 03, 2019 Mar NEWA

PERPHENAZINE

TABLET; ORAL  
PERPHENAZINE

AB RISING PHARMS 2MG  
AB 4MG  
AB 8MG  
AB 16MG

A205056 001 Mar 01, 2019 Feb NEWA  
A205056 002 Mar 01, 2019 Feb NEWA  
A205056 003 Mar 01, 2019 Feb NEWA  
A205056 004 Mar 01, 2019 Feb NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

AP FRESENIUS KABI USA 10MG/ML (10MG/ML)  
AP 50MG/5ML (10MG/ML)  
AP 100MG/10ML (10MG/ML)  
AP SANDOZ INC 10MG/ML (10MG/ML)  
AP 50MG/5ML (10MG/ML)  
AP 100MG/10ML (10MG/ML)

A210665 001 Jan 29, 2019 Jan NEWA  
A210666 001 Jan 30, 2019 Jan NEWA  
A210666 002 Jan 30, 2019 Jan NEWA  
A208905 001 Jan 31, 2019 Jan NEWA  
A208905 002 Jan 31, 2019 Jan NEWA  
A208905 003 Jan 31, 2019 Jan NEWA

SOLUTION/DROPS; OPHTHALMIC  
PHENYLEPHRINE HYDROCHLORIDE

AT +! AKORN INC 2.5%  
AT +! 10%  
AT +! PARAGON BIOTECK 2.5%  
AT +! 10%

N207926 001 Jan 15, 2015 Jan CTEC  
N207926 002 Jan 15, 2015 Jan CTEC  
N203510 001 Mar 21, 2013 Jan CTEC  
N203510 002 Mar 21, 2013 Jan CTEC

PHENYTOIN SODIUM

INJECTABLE; INJECTION  
PHENYTOIN SODIUM

@ LUITPOLD 50MG/ML

A040781 001 Dec 04, 2007 Feb DISC

PHYTONADIONE

TABLET; ORAL  
MEPHYTON

AB +! BAUSCH 5MG  
AB +! VALEANT PHARMS INTL 5MG  
PHYTONADIONE  
AB ZYDUS 5MG

N010104 003 Feb CAHN  
N010104 003 Jan CAHN  
A210189 001 Feb 20, 2019 Feb NEWA

PIMAVANSERIN TARTRATE

TABLET; ORAL  
NUPLAZID

+ @ ACADIA PHARMS INC EQ 17MG BASE

N207318 001 Apr 29, 2016 Jan DISC



PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION  
MAXAIR

>A>	@ BAUSCH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Mar CAHN
>D>	@ VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Mar CAHN

PIROXICAMCAPSULE; ORAL  
PIROXICAM

	@ BRECKENRIDGE PHARM	10MG	A208991	001	Feb 21, 2018	Jan DISC
	@	20MG	A208991	002	Feb 21, 2018	Jan DISC
AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

>A>	AB	MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
>A>	AB		EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
>A>	AB		EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA

PLECANATIDE

TABLET; ORAL

TRULANCE

>A>	+!	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
>D>	+!	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Mar CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
AB		10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

SOLUTION; ORAL

POTASSIUM CHLORIDE

>A>	AA	PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
>A>	AA		40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M15

>D>		UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
>A>	AB1		15MEQ	A074726	003	Jun 06, 2003	Mar CTEC

POTASSIUM CHLORIDE

	AB2	PII	8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
>A>	AB1		10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
	AB2		10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
>A>	AB1		15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
>A>	AB1		20MEQ	A206630	003	Mar 29, 2019	Mar NEWA

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

>A>	+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
>A>	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN
>D>	+	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
>D>	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
----	--------------	----------------	---------	-----	--------------	----------

PROGESTERONEINJECTABLE; INJECTION  
PROGESTERONE

>D>	AO	LUITPOLD	50MG/ML	A 090845	001	Jun 22, 2009	Mar	DISC
>A>		@	50MG/ML	A 090845	001	Jun 22, 2009	Mar	DISC

PROMETHAZINE HYDROCHLORIDETABLET; ORAL  
PROMETHAZINE HYDROCHLORIDE

>D>		IMPAX LABS	12.5MG	A 040791	002	Feb 12, 2008	Mar	DISC
>A>		@	12.5MG	A 040791	002	Feb 12, 2008	Mar	DISC
>D>			25MG	A 040791	003	Feb 12, 2008	Mar	DISC
>A>		@	25MG	A 040791	003	Feb 12, 2008	Mar	DISC

PROPRANOLOL HYDROCHLORIDETABLET; ORAL  
PROPRANOLOL HYDROCHLORIDE

>D>		@ ANDA REPOSITORY	10MG	A 070319	001	Oct 22, 1985	Mar	CAHN
>D>		@	20MG	A 070320	001	Oct 22, 1985	Mar	CAHN
>D>		@	40MG	A 070103	001	Oct 22, 1985	Mar	CAHN
>D>		@	60MG	A 070321	001	Sep 24, 1986	Mar	CAHN
>D>		@	80MG	A 070322	001	Aug 04, 1986	Mar	CAHN
>A>		@ INNOGENIX	10MG	A 070319	001	Oct 22, 1985	Mar	CAHN
>A>		@	10MG	A 070319	001	Oct 22, 1985	Mar	CAHN
>A>		@	20MG	A 070320	001	Oct 22, 1985	Mar	CAHN
>A>		@	40MG	A 070103	001	Oct 22, 1985	Mar	CAHN
>A>		@	60MG	A 070321	001	Sep 24, 1986	Mar	CAHN
>A>		@	60MG	A 070321	001	Sep 24, 1986	Mar	CAHN
>A>		@	80MG	A 070322	001	Aug 04, 1986	Mar	CAHN

PYRIDOSTIGMINE BROMIDEINJECTABLE; INJECTION  
MESTINON

AP	+	BAUSCH	5MG/ML	N 009830	001		Feb	CAHN
----	---	--------	--------	----------	-----	--	-----	------

SYRUP; ORAL  
MESTINON

AA	+	BAUSCH	60MG/5ML	N 015193	001		Feb	CFTG
	+		60MG/5ML	N 015193	001		Feb	CAHN

PYRIDOSTIGMINE BROMIDE  
NOVITIUM PHARMA

AA			60MG/5ML	A 211694	001	Mar 08, 2019	Feb	NFTG
----	--	--	----------	----------	-----	--------------	-----	------

TABLET; ORAL  
MESTINON

AB	+	BAUSCH	60MG	N 009829	002		Feb	CAHN
----	---	--------	------	----------	-----	--	-----	------

TABLET, EXTENDED RELEASE; ORAL  
MESTINON

AB	+	BAUSCH	180MG	N 011665	001		Feb	CAHN
----	---	--------	-------	----------	-----	--	-----	------

QUININE SULFATECAPSULE; ORAL  
QUININE SULFATE

>D>	AB	MYLAN PHARMS INC	324MG	A 202581	001	Dec 14, 2012	Mar	DISC
>A>		@	324MG	A 202581	001	Dec 14, 2012	Mar	DISC

RABEPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL  
RABEPRAZOLE SODIUM

AB		RUBICON	20MG	A 204237	001	Nov 18, 2015	Feb	CAHN
----	--	---------	------	----------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDECAPSULE; ORAL  
RANITIDINE HYDROCHLORIDE

>A>	AB	APPCO PHARMA LLC	EQ 150MG BASE	A 211893	001	Apr 05, 2019	Mar	NEWA
>A>	AB		EQ 300MG BASE	A 211893	002	Apr 05, 2019	Mar	NEWA

SYRUP; ORAL  
RANITIDINE HYDROCHLORIDE

AA		TORRENT	EQ 15MG BASE/ML	A 090102	001	May 26, 2009	Jan	CAHN
----	--	---------	-----------------	----------	-----	--------------	-----	------

TABLET; ORAL  
RANITIDINE HYDROCHLORIDE

AB		HERITAGE PHARMA	EQ 150MG BASE	A 075165	001	Sep 30, 1998	Feb	CAHN
AB			EQ 300MG BASE	A 075165	002	Sep 30, 1998	Feb	CAHN
AB		VKT PHARMA PVT LTD	EQ 150MG BASE	A 211289	001	Jan 31, 2019	Jan	NEWA

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

AB		EQ 300MG BASE		A211289	002	Jan 31, 2019	Jan NEWA
----	--	---------------	--	---------	-----	--------------	----------

RANOLAZINE

## TABLET, EXTENDED RELEASE;ORAL

## RANEXA

AB	+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
----	---	--------	-------	---------	-----	--------------	----------

AB	+	!	1GM	N021526	001	Feb 12, 2007	Feb CTEC
----	---	---	-----	---------	-----	--------------	----------

## RANOLAZINE

AB		LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
----	--	-----------	-------	---------	-----	--------------	----------

AB			1GM	A201046	002	Jul 29, 2013	Feb CMFD
----	--	--	-----	---------	-----	--------------	----------

RASAGILINE MESYLATE

## TABLET;ORAL

## RASAGILINE MESYLATE

>A>	AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
-----	----	------------	---------------	---------	-----	--------------	----------

>A>	AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA
-----	----	--	-------------	---------	-----	--------------	----------

REPAGLINIDE

## TABLET;ORAL

## PRANDIN

>D>							
-----	--	--	--	--	--	--	--

>D>	AB	+	GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
-----	----	---	-----------------	-------	---------	-----	--------------	----------

>A>		+	@	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
-----	--	---	---	-------	---------	-----	--------------	----------

>D>	AB	+		1MG	N020741	002	Dec 22, 1997	Mar DISC
-----	----	---	--	-----	---------	-----	--------------	----------

>A>		+	@	1MG	N020741	002	Dec 22, 1997	Mar DISC
-----	--	---	---	-----	---------	-----	--------------	----------

>D>	AB	+	!	2MG	N020741	003	Dec 22, 1997	Mar DISC
-----	----	---	---	-----	---------	-----	--------------	----------

>A>		+	@	2MG	N020741	003	Dec 22, 1997	Mar DISC
-----	--	---	---	-----	---------	-----	--------------	----------

## REPAGLINIDE

>D>	AB		AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
-----	----	--	----------------------	-----	---------	-----	--------------	----------

>A>	AB	!		2MG	A203820	003	Jan 22, 2014	Mar CHRS
-----	----	---	--	-----	---------	-----	--------------	----------

## @ MYLAN PHARMS INC

				0.5MG	A090252	001	Aug 23, 2013	Feb DISC
--	--	--	--	-------	---------	-----	--------------	----------

RETAPAMULIN

## OINTMENT;TOPICAL

## ALTABAX

>A>		+	!	ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
-----	--	---	---	----------	----	---------	-----	--------------	----------

>D>		+	!	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Mar CAHN
-----	--	---	---	-----------------	----	---------	-----	--------------	----------

RIBAVIRIN

## TABLET;ORAL

## RIBAVIRIN

AB		BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

AB			400MG	A202546	002	Aug 12, 2014	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

AB			500MG	A202546	003	Aug 12, 2014	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

AB			600MG	A202546	004	Aug 12, 2014	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

RILUZOLE

## TABLET;ORAL

## RILUZOLE

>D>	AB		DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
-----	----	--	---------------------	------	---------	-----	--------------	----------

>A>		@		50MG	A204430	001	Oct 16, 2018	Mar DISC
-----	--	---	--	------	---------	-----	--------------	----------

RISEDRONATE SODIUM

## TABLET;ORAL

## RISEDRONATE SODIUM

AB		HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Feb NEWA
----	--	-------------------	------	---------	-----	--------------	----------

## TABLET, DELAYED RELEASE;ORAL

## RISEDRONATE SODIUM

	@	ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC
--	---	--------------	------	---------	-----	--------------	----------

RISPERIDONE

## SOLUTION;ORAL

## RISPERIDONE

AA		TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	--	---------	--------	---------	-----	--------------	----------

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL  
RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb	NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb	NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb	NEWA

ROFLUMILASTTABLET;ORAL  
ROFLUMILAST

>A>	AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar	NEWA
-----	----	------------	--------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDETABLET;ORAL  
ROPINIROLE HYDROCHLORIDE

>D>	AB	APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar	CAHN
>D>	AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar	CAHN
	AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb	CAHN
	AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb	CAHN
	AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb	CAHN
	AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb	CAHN
	AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb	CAHN
	AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb	CAHN
	AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb	CAHN
>A>	AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar	CAHN
>A>	AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar	CAHN

ROSUVASTATIN CALCIUMTABLET;ORAL  
ROSUVASTATIN CALCIUM

>A>	AB	UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Mar	NEWA
>A>	AB		10MG	A207626	002	Apr 09, 2019	Mar	NEWA
>A>	AB		20MG	A207626	003	Apr 09, 2019	Mar	NEWA
>A>	AB		40MG	A207626	004	Apr 09, 2019	Mar	NEWA
	AB	ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Feb	NEWA
	AB		10MG	A206513	002	Mar 01, 2019	Feb	NEWA
	AB		20MG	A206513	003	Mar 01, 2019	Feb	NEWA
	AB		40MG	A206513	004	Mar 01, 2019	Feb	NEWA

RUFINAMIDETABLET;ORAL  
RUFINAMIDE

	@	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	Feb	DISC
	@		400MG	A205095	002	May 16, 2016	Feb	DISC

SELEGILINE HYDROCHLORIDECAPSULE;ORAL  
SELEGILINE HYDROCHLORIDE

>A>	AB	PACK PHARMS LLC	5MG	A206803	001	Apr 02, 2019	Mar	NEWA
-----	----	-----------------	-----	---------	-----	--------------	-----	------

TABLET;ORAL  
SELEGILINE HYDROCHLORIDE

>D>	AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Mar	CAHN
>A>	AB	KENTON	5MG	A074912	001	Apr 30, 1998	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
ZELAPAR

>A>	+	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN
>D>	+	VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	+ GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+!	800MG	N021179	002	Jul 12, 2000	Feb CFTG

SEVELAMER HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB		800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

>A>	AB	LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
>A>	AB		EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
>A>	AB		EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
>A>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
>A>	AB		EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
>A>	AB		EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

>A>	AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar CAHN
>A>	AB		10MG	A090383	002	Sep 16, 2011	Mar CAHN
>A>	AB		20MG	A090383	003	Sep 16, 2011	Mar CAHN
>A>	AB		40MG	A090383	004	Sep 16, 2011	Mar CAHN
>A>	AB		80MG	A090383	005	Sep 16, 2011	Mar CAHN
>D>	AB	VIVA HLTHCARE	5MG	A090383	001	Sep 16, 2011	Mar CAHN
>D>	AB		10MG	A090383	002	Sep 16, 2011	Mar CAHN
>D>	AB		20MG	A090383	003	Sep 16, 2011	Mar CAHN
>D>	AB		40MG	A090383	004	Sep 16, 2011	Mar CAHN
>D>	AB		80MG	A090383	005	Sep 16, 2011	Mar CAHN

>A> SIPONIMOD

&gt;A&gt; TABLET;ORAL

&gt;A&gt; MAYZENT

>A>	+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar NEWA
>A>	+	!	2MG	N209884	002	Mar 26, 2019	Mar NEWA

SIROLIMUS

SOLUTION;ORAL

RAPAMUNE

AA	+!	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan CFTG
AA		NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan NFTG

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb NEWA
----	--	--------------------	-----------	---------	-----	--------------	----------

SODIUM CHROMATE CR-51

INJECTABLE;INJECTION

SODIUM CHROMATE CR 51

@ CURIUM

100uCi/ML

N016708 001

Jan CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

@ CURIUM

0.8-100mCi

N016515 002

Jan CAHN

+

@

@

0.8-100mCi

N016517 001

Jan CAHN

15-100uCi

N016517 002

Jan CAHN

		SOLUTION;ORAL							
		SODIUM IODIDE I 131							
		+ @ CURIUM	3.5-150mCi/VIAL		N016515	001			Jan CAHN
		<u>SODIUM NITROPRUSSIDE</u>							
		INJECTABLE;INJECTION							
		SODIUM NITROPRUSSIDE							
>A>	AP	DR REDDYS LABS LTD	25MG/ML		A210114	001	Apr 10, 2019		Mar NEWA
		<u>SODIUM PHENYLBUTYRATE</u>							
		POWDER;ORAL							
		BUPHENYL							
AB		+! HORIZON THERAP	3GM/TEASPOONFUL		N020573	001	Apr 30, 1996		Feb CAHN
		TABLET;ORAL							
		BUPHENYL							
AB		+! HORIZON THERAP	500MG		N020572	001	May 13, 1996		Feb CAHN
		<u>STAVUDINE</u>							
>D>		FOR SOLUTION;ORAL							
>D>		ZERIT							
>D>		+! BRISTOL-MYERS SQUIBB	1MG/ML		N020413	001	Sep 06, 1996		Mar DISC
>A>		+ @	1MG/ML		N020413	001	Sep 06, 1996		Mar DISC
		<u>STRONTIUM CHLORIDE SR-89</u>							
		INJECTABLE;INJECTION							
		METASTRON							
AP		+! Q BIOMED	1mCi/ML		N020134	001	Jun 18, 1993		Jan CAHN
		<u>SUCCINYLCHOLINE CHLORIDE</u>							
		INJECTABLE;INJECTION							
		SUCCINYLCHOLINE CHLORIDE							
AP		AMRING PHARMS	20MG/ML		A210231	001	Jun 04, 2018		Jan CAHN
		<u>SUMATRIPTAN</u>							
		SPRAY;NASAL							
		TOSYMRA							
		+! DR REDDYS LABS LTD	10MG/SPRAY		N210884	001	Jan 25, 2019		Jan NEWA
		<u>TACROLIMUS</u>							
		OINTMENT;TOPICAL							
		TACROLIMUS							
AB		ACCORD HLTHCARE	0.03%		A211688	001	Jan 31, 2019		Jan NEWA
AB			0.1%		A211688	002	Jan 31, 2019		Jan NEWA
		<u>TADALAFIL</u>							
		TABLET;ORAL							
		ALYQ							
AB2		TEVA PHARMS USA	20MG		A209942	001	Feb 05, 2019		Jan NEWA
		TADALAFIL							
>A>	AB	ACCORD HLTHCARE	2.5MG		A209167	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A209167	002	Mar 26, 2019		Mar NEWA
>A>	AB1		20MG		A209167	004	Mar 26, 2019		Mar NEWA
>A>	AB	AJANTA PHARMA LTD	2.5MG		A209654	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A209654	002	Mar 26, 2019		Mar NEWA
>A>	AB		10MG		A209654	003	Mar 26, 2019		Mar NEWA
>A>	AB1		20MG		A209654	004	Mar 26, 2019		Mar NEWA
	AB2		20MG		A210392	001	Feb 05, 2019		Jan NEWA
>A>	AB	ALEMBIC PHARMS LTD	2.5MG		A204809	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A204809	002	Mar 26, 2019		Mar NEWA
>A>	AB		10MG		A204809	003	Mar 26, 2019		Mar NEWA
>A>	AB1		20MG		A204809	004	Mar 26, 2019		Mar NEWA
>A>	AB	AMNEAL PHARMS CO	2.5MG		A209744	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A209744	002	Mar 26, 2019		Mar NEWA
>A>	AB		10MG		A209744	003	Mar 26, 2019		Mar NEWA
>A>	AB1		20MG		A209744	004	Mar 26, 2019		Mar NEWA
>A>	AB	AUROBINDO PHARMA LTD	2.5MG		A206285	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A206285	002	Mar 26, 2019		Mar NEWA
>A>	AB		10MG		A206285	003	Mar 26, 2019		Mar NEWA
>A>	AB1		20MG		A206285	004	Mar 26, 2019		Mar NEWA
	AB2		20MG		A206286	001	Feb 05, 2019		Jan NEWA
>A>	AB	CIPLA	2.5MG		A209539	001	Mar 26, 2019		Mar NEWA
>A>	AB		5MG		A209539	002	Mar 26, 2019		Mar NEWA

TABLET;ORAL  
TADALAFIL

>A>	AB		10MG	A209539	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A209539	004	Mar 26, 2019	Mar	NEWA
	AB2		20MG	A210255	001	Feb 05, 2019	Jan	NEWA
>A>	AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A210069	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A210069	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A210069	004	Mar 26, 2019	Mar	NEWA
	AB2		20MG	A210145	001	Feb 05, 2019	Jan	NEWA
>A>	AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A209908	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A209908	003	Mar 26, 2019	Mar	NEWA
	AB2		20MG	A209907	001	Feb 05, 2019	Jan	NEWA
>A>	AB1		20MG	A209908	004	Mar 26, 2019	Mar	NEWA
>A>	AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A210567	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A210567	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A210567	004	Mar 26, 2019	Mar	NEWA
	AB2		20MG	A210572	001	Feb 05, 2019	Jan	NEWA
>A>	AB	QILU PHARM CO LTD	2.5MG	A210420	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A210420	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A210420	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A210420	004	Mar 26, 2019	Mar	NEWA
>A>	AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A208934	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A208934	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A208934	004	Mar 26, 2019	Mar	NEWA
>A>	AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A211335	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A211335	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A211335	004	Mar 26, 2019	Mar	NEWA
>A>	AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A211839	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A211839	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A211839	004	Mar 26, 2019	Mar	NEWA
>A>	AB2		20MG	A212062	001	Mar 26, 2019	Mar	NEWA
>A>	AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A209250	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A209250	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A209250	004	Mar 26, 2019	Mar	NEWA
>A>	AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Mar	NEWA
>A>	AB		5MG	A205885	002	Mar 29, 2019	Mar	NEWA
>A>	AB		10MG	A205885	003	Mar 29, 2019	Mar	NEWA
>A>	AB1		20MG	A205885	004	Mar 29, 2019	Mar	NEWA
>A>	AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar	NEWA
>A>	AB		5MG	A206693	002	Mar 26, 2019	Mar	NEWA
>A>	AB		10MG	A206693	003	Mar 26, 2019	Mar	NEWA
>A>	AB1		20MG	A206693	004	Mar 26, 2019	Mar	NEWA

TAZAROTENE

CREAM;TOPICAL  
TAZAROTENE

AB		FOUGERA PHARMS INC	1%	A211175	001	Jan 28, 2019	Jan	NEWA
----	--	--------------------	----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION  
TECHNESCAN MAG3

+!	CURIUM		N/A	N019882	001	Jun 15, 1990	Jan	CAHN
----	--------	--	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE;INJECTION  
TECHNESCAN

+!	CURIUM		N/A	N018321	001		Jan	CAHN
----	--------	--	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION  
TECHNESCAN PYP KIT

AP		CURIUM	N/A	N017538	001		Jan	CAHN
----	--	--------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M RED BLOOD CELL KITINJECTABLE; INJECTION  
ULTRATAG

+! CURIUM N/A N019981 001 Jun 10, 1991 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS  
ULTRA-TECHNEKOW FM+! CURIUM 1-19 CI/GENERATOR N017243 003 Feb 18, 2014 Jan CAHN  
@ 0.25-3 CI/GENERATOR N017243 002 Jan CAHNSOLUTION; INTRAVENOUS, ORAL  
TECHNETIUM TC 99M GENERATOR

+ @ GE HEALTHCARE 68-2703mCi/GENERATOR N017693 002 Dec 13, 2013 Feb DISC

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	CIPLA	20MG	A078710	001	Jan 08, 2014	Feb	CAHN
	@	40MG	A078710	002	Jan 08, 2014	Feb	CAHN
	@	80MG	A078710	003	Jan 08, 2014	Feb	CAHN
AB	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Feb	NEWA
AB		40MG	A207843	002	Feb 19, 2019	Feb	NEWA
AB		80MG	A207843	003	Feb 19, 2019	Feb	NEWA
>D> AB	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar	DISC
>A>	@	20MG	A207016	001	Oct 03, 2017	Mar	DISC
>D> AB		40MG	A207016	002	Oct 03, 2017	Mar	DISC
>A>	@	40MG	A207016	002	Oct 03, 2017	Mar	DISC
>D> AB		80MG	A207016	003	Oct 03, 2017	Mar	DISC
>A>	@	80MG	A207016	003	Oct 03, 2017	Mar	DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb	DISC

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

	@ APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan	DISC
	@	20MG	A204159	002	Jul 05, 2018	Jan	DISC
	@	100MG	A204159	003	Jul 05, 2018	Jan	DISC
	@	140MG	A204159	004	Jul 05, 2018	Jan	DISC
	@	180MG	A204159	005	Jul 05, 2018	Jan	DISC
	@	250MG	A204159	006	Jul 05, 2018	Jan	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ APOTEX INC 300MG A206481 001 Jul 26, 2018 Jan DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb	CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb	CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb	CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb	CAHN
>A> AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar	CAHN
>A> AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar	CAHN
>A> AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar	CAHN
>A> AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar	CAHN
>D> AB	IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar	CAHN
>D> AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar	CAHN
>D> AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar	CAHN
>D> AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar	CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb	DISC
	@	14MG	A209613	002	Sep 28, 2018	Feb	DISC
	@ APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan	DISC
	@	14MG	A209601	002	Nov 02, 2018	Jan	DISC
	@ AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb	DISC
	@	14MG	A209638	002	Oct 26, 2018	Feb	DISC



TABLET;ORAL

## TERIFLUNOMIDE

>D>	AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
>A>	@		7MG	A209700	001	Sep 04, 2018	Mar DISC
>D>	AB		14MG	A209700	002	Sep 04, 2018	Mar DISC
>A>	@		14MG	A209700	002	Sep 04, 2018	Mar DISC
	@	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@		14MG	A209549	002	Jul 27, 2018	Feb DISC

TESTOSTERONE

## GEL;TRANSDERMAL

## TESTOSTERONE

>D>	AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar DISC
>A>	@		25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar DISC

## GEL, METERED;TRANSDERMAL

## TESTOSTERONE

>A>	AB	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar NEWA
>A>	AB	AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar NEWA
>A>	AB	DR REDDYS LABS INC	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar NEWA
>A>	AB	LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar NEWA

TESTOSTERONE CYPIONATE

## INJECTABLE;INJECTION

## TESTOSTERONE CYPIONATE

	@	LUITPOLD	200MG/ML	A207742	001	Jun 16, 2017	Feb DISC
>D>	AO	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar DISC
>A>	@		200MG/ML	A040652	001	Dec 11, 2006	Mar DISC

TESTOSTERONE UNDECANOATE

## CAPSULE;ORAL

## JATENZO

>A>	+	CLARUS	158MG	N206089	001	Mar 27, 2019	Mar NEWA
>A>	+		198MG	N206089	002	Mar 27, 2019	Mar NEWA
>A>	+	!	237MG	N206089	003	Mar 27, 2019	Mar NEWA

TETRABENAZINE

## TABLET;ORAL

## TETRABENAZINE

	@	LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Feb DISC
	@		25MG	A210544	002	Apr 20, 2018	Feb DISC
>A>	AB	WEST-WARD PHARMS INT	12.5MG	A209739	001	Apr 08, 2019	Mar NEWA
>A>	AB		25MG	A209739	002	Apr 08, 2019	Mar NEWA

TETRACAINE HYDROCHLORIDE

## SOLUTION;OPHTHALMIC

## TETRACAINE HYDROCHLORIDE

>A>		VALEANT PHARMS	0.5%	N210821	001	Mar 12, 2019	Mar NEWA
-----	--	----------------	------	---------	-----	--------------	----------

THALLOUS CHLORIDE TL-201

## INJECTABLE;INJECTION

## THALLOUS CHLORIDE TL 201

AP	+	!	CURIUM	1mCi/ML	N018150	001	Jan CAHN
----	---	---	--------	---------	---------	-----	----------

THEOPHYLLINE

## TABLET, EXTENDED RELEASE;ORAL

## THEOPHYLLINE

AB	!	HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Feb CAHN
AB	!		200MG	A089808	001	Apr 30, 1990	Feb CAHN
AB			300MG	A089763	001	Apr 30, 1990	Feb CAHN
	@		450MG	A081236	001	Nov 09, 1992	Feb CAHN

THIOTHIXENE

## CAPSULE;ORAL

## THIOTHIXENE

>D>		MYLAN	1MG	A071093	002	Jun 23, 1987	Mar CTEC
>A>	AB		1MG	A071093	002	Jun 23, 1987	Mar CTEC
>D>			2MG	A071093	003	Jun 23, 1987	Mar CTEC
>A>	AB		2MG	A071093	003	Jun 23, 1987	Mar CTEC
>D>	!		5MG	A071093	004	Jun 23, 1987	Mar CTEC
>A>	AB	!	5MG	A071093	004	Jun 23, 1987	Mar CTEC
>D>			10MG	A071093	001	Jun 23, 1987	Mar CTEC
>A>	AB		10MG	A071093	001	Jun 23, 1987	Mar CTEC

CAPSULE;ORAL  
THIOTHIXENE

>A>	AB	NOVITIUM PHARMA	1MG	A211642	001	Apr 05, 2019	Mar	NEWA
>A>	AB		2MG	A211642	002	Apr 05, 2019	Mar	NEWA
>A>	AB		5MG	A211642	003	Apr 05, 2019	Mar	NEWA
>A>	AB		10MG	A211642	004	Apr 05, 2019	Mar	NEWA

TICAGRELORTABLET;ORAL  
TICAGRELOR

AB		AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jan	NEWA
AB		HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan	NEWA
		@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb	DISC
		@	90MG	A208390	002	Sep 04, 2018	Feb	DISC

TIGECYCLINEPOWDER; INTRAVENOUS  
TIGECYCLINE

		@ AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Feb	DISC
--	--	---------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC  
TIMOPTIC

AT	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan	CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jan	CAHN
		TIMOPTIC IN OCUDOSE						
	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan	CAHN
	+		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

## CAPSULE;ORAL

## TIZANIDINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar	NEWA
>A>	AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar	NEWA
>A>	AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar	NEWA
>A>	AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar	NEWA
>A>	AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar	NEWA
	AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb	NEWA
	AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb	NEWA
	AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb	NEWA

## TABLET;ORAL

## TIZANIDINE HYDROCHLORIDE

	AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan	NEWA
	AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan	NEWA
>D>	AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar	DISC
>A>		@	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar	DISC
>D>	AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar	DISC
>A>		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar	DISC

TOBRAMYCINSOLUTION; INHALATION  
TOBRAMYCIN

>D>		@ DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar	CMFD
>A>	AN		300MG/5ML	A207080	001	Jul 09, 2018	Mar	CMFD
		@	300MG/5ML	A207080	001	Jul 09, 2018	Jan	DISC

TOLCAPONETABLET;ORAL  
TASMAR

>A>	AB	+	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar	CAHN
>A>		@		200MG	N020697	002	Jan 29, 1998	Mar	CAHN
>D>	AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CAHN
>D>		@		200MG	N020697	002	Jan 29, 1998	Mar	CAHN

TOPIRAMATECAPSULE, EXTENDED RELEASE;ORAL  
QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb	CTEC
BC	+		50MG	N205122	002	Mar 11, 2014	Feb	CTEC
BC	+		100MG	N205122	003	Mar 11, 2014	Feb	CTEC
BC	+		200MG	N205122	005	Mar 11, 2014	Feb	CTEC

TRANEXAMIC ACIDINJECTABLE; INJECTION  
TRANEXAMIC ACID

AP	ACIC PHARMS	100MG/ML	A209326	001	Feb 22, 2019	Feb	NEWA
>A>	AP	MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar CAHN
>D>	AP	VIVA HLTHCARE	100MG/ML	A206713	001	Jun 27, 2017	Mar CAHN

TREPROSTINIL DIOLAMINETABLET, EXTENDED RELEASE; ORAL  
ORENITRAM

+	!	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb CHRS
+			EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb CHRS

TRETINOINCREAM; TOPICAL  
TRETINOIN

AB1	TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan	NEWA
AB		0.1%	A211645	001	Jan 22, 2019	Jan	NEWA

TRIAMCINOLONE ACETONIDECREAM; TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan	NEWA
AT		0.1%	A210346	002	Feb 11, 2019	Jan	NEWA
AT		0.5%	A210346	003	Feb 11, 2019	Jan	NEWA

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

>D>	AB	TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Mar DISC
>A>		@	40MG/ML	A209852	001	Oct 05, 2018	Mar DISC

TRICLABENDAZOLETABLET; ORAL  
EGATEN

+	!	NOVARTIS PHARMS CORP	250MG	N208711	001	Feb 13, 2019	Feb NEWA
---	---	----------------------	-------	---------	-----	--------------	----------

TRIENTINE HYDROCHLORIDECAPSULE; ORAL  
TRIENTINE HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE; ORAL  
TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	LUPIN	300MG	A076546	001	Aug 20, 2003	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

@ LUITPOLD 100MG/ML

A091330	001	Mar 08, 2011	Feb	DISC
---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

@ LUITPOLD 100MG/ML

A091329	001	Mar 08, 2011	Feb	DISC
---------	-----	--------------	-----	------

VALSARTANTABLET; ORAL  
VALSARTAN

AB	ALKEM LABS LTD	40MG	A205536	001	Mar 12, 2019	Feb	NEWA
AB		80MG	A205536	002	Mar 12, 2019	Feb	NEWA
AB		160MG	A205536	003	Mar 12, 2019	Feb	NEWA
AB		320MG	A205536	004	Mar 12, 2019	Feb	NEWA

VANCOMYCIN HYDROCHLORIDESOLUTION; INTRAVENOUS  
VANCOMYCIN HYDROCHLORIDE

+	!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb NEWA
+	!		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb NEWA
+	!		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb NEWA
+	!		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb NEWA

VASOPRESSIN

>A>	SOLUTION;INTRAVENOUS							
>A>	VASOSTRICT							
>A>	+! PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar	CDFR	
>A>	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar	CDFR	
>D>	SOLUTION;IV (INFUSION)							
>D>	VASOSTRICT							
>D>	+! PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar	CDFR	
>D>	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar	CDFR	

VIGABATRIN

	FOR SOLUTION;ORAL							
	VIGADRONE							
>D> AA	AUCTA PHARMS	500MG/PACKET	A210196	001	Jun 21, 2018	Mar	CAHN	
>A> AA	SHANGHAI	500MG/PACKET	A210196	001	Jun 21, 2018	Mar	CAHN	

VINCRISTINE SULFATE

	INJECTABLE, LIPOSOMAL;INTRAVENOUS							
	MARQIBO KIT							
>A>	+! ACROTECH	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar	CAHN	
>D>	+! TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar	CAHN	

VINORELBINE TARTRATE

	INJECTABLE;INJECTION							
	VINORELBINE TARTRATE							
>D> AP	HOSPIRA	EQ 10MG BASE/ML	A076827	001	Jun 02, 2005	Mar	DISC	
>A>	@	EQ 10MG BASE/ML	A076827	001	Jun 02, 2005	Mar	DISC	

VORICONAZOLE

	POWDER;IV (INFUSION)							
	VORICONAZOLE							
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb	CTEC	
	TABLET;ORAL							
	VORICONAZOLE							
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb	CAHN	
AB		200MG	A206762	002	May 24, 2016	Feb	CAHN	

ZIDOVUDINE

	INJECTABLE;INJECTION							
	ZIDOVUDINE							
	@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	DISC	

ZIPRASIDONE HYDROCHLORIDE

	CAPSULE;ORAL							
	ZIPRASIDONE HYDROCHLORIDE							
AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb	CAHN	
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb	CAHN	
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb	CAHN	
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb	CAHN	

ZOLEDRONIC ACID

>A>	INJECTABLE;INTRAVENOUS							
>A>	RECLAST							
>A> AP	+! NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CDFR	
>A>	ZOLEDRONIC							
>A> AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar	CDFR	
>A>	ZOLEDRONIC ACID							
>A> AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar	CDFR	
>A> AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar	CDFR	
>A> AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar	CDFR	
>A> AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar	CDFR	
>A> AP	APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	CDFR	
>A> AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar	CDFR	
>A> AP		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar	CDFR	
>A> AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar	CDFR	
>A> AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar	CDFR	
>A> AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar	CDFR	
>A> AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar	CDFR	
>A> AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar	CDFR	
>A> AP	DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar	CDFR	
>A> AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	CDFR	

>A>	INJECTABLE; INTRAVENOUS								
>A>	ZOLEDRONIC ACID								
>A> AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	CDFR		
>A> AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar	CDFR		
>A> AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar	CDFR		
>A> AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar	CDFR		
>A> AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	CDFR		
>A> AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar	CDFR		
>A> AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar	CDFR		
>A> AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar	CDFR		
>A> AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar	CDFR		
>A>	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar	CDFR		
>A>	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar	CDFR		
>A> AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CDFR		
>A>	ZOMETA								
>A>	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar	CDFR		
>A> AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar	CDFR		
>A> AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar	CDFR		
>D>	INJECTABLE; IV (INFUSION)								
>D>	RECLAST								
>D> AP	+! NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CDFR		
>D>	ZOLEDRONIC								
>D> AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar	CDFR		
>D>	ZOLEDRONIC ACID								
>D> AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar	CDFR		
>D> AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar	CDFR		
>D> AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar	CDFR		
>D> AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar	CDFR		
>D> AP	APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	CDFR		
>D> AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar	CDFR		
>D> AP	BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar	CDFR		
>D> AP	BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar	CDFR		
>D> AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar	CDFR		
>D> AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar	CDFR		
>D> AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar	CDFR		
>A> AP		EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar	CDFR		
>D> AP		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar	CDFR		
>D> AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar	CDFR		
>D> AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar	CDFR		
>D> AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar	CDFR		
>D> AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar	CDFR		
>D> AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar	CDFR		
>D> AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar	CDFR		
>D> AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar	CDFR		
>D> AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar	CDFR		
>D> AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar	CDFR		
>D>	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar	CDFR		
>D>	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar	CDFR		
>D> AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CDFR		
>D>	ZOMETA								
>D>	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar	CDFR		
>D> AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar	CDFR		
>D> AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar	CDFR		
>A>	SOLUTION; INTRAVENOUS								
>A>	ZOLEDRONIC ACID								
>A>	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar	CDFR		
>D>	SOLUTION; IV (INFUSION)								
>D>	ZOLEDRONIC ACID								
>D>	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG	N204016	001	Dec 28, 2015	Mar	CDFR		

>D>	SOLUTION;IV (INFUSION)						
>D>	ZOLEDRONIC ACID						
		BASE/ML)					
	<u>ZOLPIDEM TARTRATE</u>						
	SPRAY, METERED;ORAL						
	ZOLPIMIST						
	+! AYTU	5MG/SPRAY		N022196	001	Dec 19, 2008	Feb CAHN
	TABLET;SUBLINGUAL						
>D>	INTERMEZZO						
>D> AB	+ PURDUE PHARMA	1.75MG		N022328	001	Nov 23, 2011	Mar DISC
>A>	+ @	1.75MG		N022328	001	Nov 23, 2011	Mar DISC
>D> AB	+!	3.5MG		N022328	002	Nov 23, 2011	Mar DISC
>A>	+ @	3.5MG		N022328	002	Nov 23, 2011	Mar DISC
	ZOLPIDEM TARTRATE						
>D> AB	NOVEL LABS INC	3.5MG		A204299	002	Jun 03, 2015	Mar CHRS
>A> AB	!	3.5MG		A204299	002	Jun 03, 2015	Mar CHRS

ACETAMINOPHEN

SUPPOSITORY;RECTAL  
ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb	CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb	CAHN
@	650MG	N018060	002		Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

>D>	HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Mar	DISC
>A>	@	650MG	A207035	001	May 31, 2018	Mar	DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	NEWA
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan	CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Jan	CMFD
-------	-------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ @ BAYER HEALTHCARE LLC	8MG	N007638	001		Feb	CRLD
+ @	12MG	N007638	002		Jan	DISC
CHLORPHENIRAMINE MALEATE						
! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan	CHRS

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019	Jan	NEWA
----------------------	--	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG;220MG	A207597	001	Jan 25, 2019	Jan	NEWA
-------------------	------------	---------	-----	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

>D>	OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Mar	DISC
>A>	@	600MG	A209254	001	Jul 16, 2018	Mar	DISC
>D>		1.2GM	A209254	002	Jul 16, 2018	Mar	DISC
>A>	@	1.2GM	A209254	002	Jul 16, 2018	Mar	DISC

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

@ GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb	DISC
-----------------	-----------	---------	-----	--------------	-----	------

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL A-D

+! KRAMER	1%	N020310	001	Oct 10, 1997	Jan	CAHN
-----------	----	---------	-----	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ZADITOR

! ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Feb	CTNA
--------------------	----------------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	PERRIGO R AND D	5MG	A211983	001	Mar 26, 2019	Mar	NEWA
-----	-----------------	-----	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@ APOTEX INC 1.5MG

A205329 001 Sep 18, 2018 Jan DISC

LORATADINE

CAPSULE;ORAL

LORATADINE

>D>	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	Mar	DISC
-----	----------------	------	---------	-----	--------------	-----	------

>A>	@	10MG	A202538	001	Dec 21, 2018	Mar	DISC
-----	---	------	---------	-----	--------------	-----	------

TABLET;ORAL

LORATADINE

>A>	GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019	Mar	CAHN
-----	---------------	------	---------	-----	--------------	-----	------

>D>	NEWGEN PHARMS LLC	10MG	A207569	001	Mar 12, 2019	Mar	CAHN
-----	-------------------	------	---------	-----	--------------	-----	------

		10MG	A207569	001	Mar 12, 2019	Feb	NEWA
--	--	------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

LORATADINE

>A>	SUN PHARM	5MG	A210088	001	Apr 16, 2018	Mar	CAHN
-----	-----------	-----	---------	-----	--------------	-----	------

>D>	SUN PHARMA GLOBAL	5MG	A210088	001	Apr 16, 2018	Mar	CAHN
-----	-------------------	-----	---------	-----	--------------	-----	------

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS &amp; COLD

>D>	+! BAYER	200MG;120MG	N021076	001	Nov 29, 1999	Mar	CPOT
-----	----------	-------------	---------	-----	--------------	-----	------

>A>	+!	EQ 200MG BASE;120MG	N021076	001	Nov 29, 1999	Mar	CPOT
-----	----	---------------------	---------	-----	--------------	-----	------

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

PLD ACQUISITIONS EQ 2MG BASE

A207868 001 Feb 07, 2019 Feb NEWA

EQ 4MG BASE

A207868 002 Feb 07, 2019 Feb NEWA

@ WATSON LABS INC EQ 2MG BASE

A209206 001 Jun 26, 2018 Feb DISC

@ EQ 4MG BASE

A209206 002 Jun 26, 2018 Feb DISC

@ WATSON LABS TEVA EQ 2MG BASE

A209519 001 Jul 02, 2018 Feb DISC

@ EQ 4MG BASE

A209519 002 Jul 02, 2018 Feb DISC

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX INC 20MG

A210070 001 Feb 11, 2019 Jan NEWA

SODIUM FLUORIDE; TRICLOSAN

&gt;D&gt; PASTE;DENTAL

&gt;D&gt; COLGATE TOTAL

>D>	+! COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar	DISC
-----	----------------------	------------	---------	-----	--------------	-----	------

>A>	+ @	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar	DISC
-----	-----	------------	---------	-----	--------------	-----	------



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2019**

NO MARCH 2019 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327	001				PC	Apr 29, 2019
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259	001	10167291	Jul 01, 2036	DP U-2145		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	002	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653	003	8461137	Feb 22, 2031	DS DP		
		8748413	Jul 10, 2030	DS DP		
		8828978	Jul 01, 2030	DP		
		9132125	Jul 01, 2030	DS DP	U-2249	
		9549923	Jul 01, 2030	DS DP		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001				>A> NC	Mar 29, 2022
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	001				>A> ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	002				>A> ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	003				>A> ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10124131	May 18, 2031	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	10022510	May 18, 2031	DP		
		10124131	May 18, 2031	DP		
		6701917	Jun 23, 2021	DP		
		6718972	Jun 23, 2021	DP		
		6748947	Jun 23, 2021	DP		
		6871646	Jun 23, 2021	DP		
		7540282	May 06, 2023	DP		
		8006690	Jun 23, 2021	DP		
		8651103	Mar 26, 2028	DP		
		8978966	Jan 13, 2032	DP		
		9216260	Jun 28, 2031	DP		
		9463288	May 19, 2025	DP		
		9731087	May 18, 2031	DP		
		9782550	Aug 28, 2035	DP		
		9782551	Aug 28, 2035	DP		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001	10183012	Nov 26, 2028	U-2104		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002	10183012	Nov 26, 2028	U-2104		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001	>A> 10213393	Feb 15, 2038	U-20		
		>A> 10213394	Feb 15, 2038	U-2497		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	>A> 10213393	Feb 15, 2038	U-20			
	>A> 10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	>A> 10213393	Feb 15, 2038	U-20			
	>A> 10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	>A> 10213393	Feb 15, 2038	U-20			
	>A> 10213394	Feb 15, 2038	U-2497			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	>A> 10226458	Nov 07, 2032	U-543			
	>A> 10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	>A> 10226458	Nov 07, 2032	U-543			
	>A> 10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	>A> 10226458	Nov 07, 2032	U-543			
	>A> 10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	>A> 10226458	Nov 07, 2032	U-543			
	>A> 10238651	Mar 19, 2035	U-2402			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	>A> 6479535	May 06, 2024	DP U-594			
	>A> 6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	>A> 7417148	Dec 11, 2025	U-1283			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
<u>CERTINIB - ZYKADIA</u>						
N 211225 001				>A> NCE		Apr 29, 2019
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	>A> 10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-238	Feb 22, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				M-238	Feb 22, 2022
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	002	>A> 9889115	Jun 23, 2019	U-1305		
		>A> 9889115*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	004	>A> 9889115	Jun 23, 2019	U-1305		
		>A> 9889115*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	005	>A> 9889115	Jun 23, 2019	U-1305		
		>A> 9889115*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976	006	>A> 9889115	Jun 23, 2019	U-1305		
		>A> 9889115*PED	Dec 23, 2019			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895	001	>A> 9889115	Jun 23, 2019	U-1305		
		>A> 9889115*PED	Dec 23, 2019			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	>A> 10201542	Oct 18, 2033	DP U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA XR</u>						
N 208624	001	>A> 10201541	May 17, 2032	DP		
		>A> 10201584	May 17, 2032	U-1889		
<u>DASATINIB - SPRYCEL</u>						
N 021986	001				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	002				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	003				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	004				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	005				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	001				>A> PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	002				>A> PC	Apr 05, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	003				>A> PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910	001				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910	002				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU</u>						
N 206910	003				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				>A> M-239	Dec 12, 2021
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				>A> M-239	Dec 12, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328	Jun 28, 2021	U-735		
		8703156	Oct 29, 2029	DP U-735		
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742	001	8409606	May 14, 2030	DP	NP	Nov 30, 2021
		8563027	Feb 12, 2030	U-2487		
		9254267	Sep 11, 2024	DP		
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912	001	10159683	May 23, 2034	DP		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	>A> 10238620	May 18, 2027	U-620		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	>A> 10238620	May 18, 2027	U-620		
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001	10058564	Apr 05, 2022	U-1063		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	001	7160870	Nov 20, 2022	DS DP U-1306		
		7160870	Nov 20, 2022	DS DP U-2451		
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021	U-1306		
		7332481	May 24, 2021	U-2451		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP		
		7452874*PED	Nov 24, 2021			
		7473686	May 24, 2021	DS DP U-1306		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021		U-1306		
	7790704	May 24, 2021		U-2451		
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023		U-1306		
	7795293	May 21, 2023		U-2451		
	7795293*PED	Nov 21, 2023				
>A>	8052993	Aug 01, 2027	DP U-1306			
>A>	8052993	Aug 01, 2027	DP U-1575			
>A>	8052993	Aug 01, 2027	DP U-2451			
>A>	8052993	Aug 01, 2027	DP U-930			
>A>	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021		U-1306		
	7332481	May 24, 2021		U-2451		
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
>A>	7547719	Jul 13, 2025	DS DP U-1306			
>A>	7547719	Jul 13, 2025	DS DP U-1575			
>A>	7547719	Jul 13, 2025	DS DP U-2451			
>A>	7547719	Jul 13, 2025	DS DP U-2452			
>A>	7547719	Jul 13, 2025	DS DP U-930			
>A>	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021		U-1306		
	7790704	May 24, 2021		U-2451		
	7790704*PED	Nov 24, 2021				
>A>	7795293	May 21, 2023		U-1306		
>A>	7795293	May 21, 2023		U-2451		
>A>	7795293	May 21, 2023		U-930		
>A>	7795293*PED	Nov 21, 2023				
>A>	8052994	Aug 01, 2027	DP U-1306			
>A>	8052994	Aug 01, 2027	DP U-2451			
>A>	8052994	Aug 01, 2027	DP U-930			
>A>	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021		U-1306		
	7332481	May 24, 2021		U-2451		
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-2451			
	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-2451			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293*PED	Nov 21, 2023				
	>A> 8062665	Aug 01, 2027	DP U-1306			
	>A> 8062665	Aug 01, 2027	DP U-2451			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	>A> 8071129	Aug 01, 2027	DP U-1306			
	>A> 8071129	Aug 01, 2027	DP U-2451			
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1736			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1736			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1736			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1736			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1736			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1736			
	>A> 7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1736			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1736			
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1736			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1736			
	>A> 7547719	Jul 13, 2025	DS DP U-2452			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1736			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	>A> 10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	>A> 10213415	Mar 14, 2025	DS U-2152			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAIVA</u>						
N 211109 001	>A> 8796245	Aug 07, 2029	U-2380			
	>A> 8906887	Dec 28, 2030	DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	>A> 8785500	Jul 09, 2031	U-2502		>A> NCE*	Mar 05, 2024
	>A> 9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2020	DP U-1577		I-790	Nov 06, 2020
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	>A> 6774122	Jan 09, 2021	U-1826			
	>A> 6774122	Jan 09, 2021	U-2108			
	>A> 6774122	Jan 09, 2021	U-2163			
	>A> 6774122	Jan 09, 2021	U-2504			
	>A> 6774122	Jan 09, 2021	U-596			
	>A> 6774122*PED	Jul 09, 2021				
	>A> 7456160	Jan 09, 2021	U-1826			
	>A> 7456160	Jan 09, 2021	U-2108			
	>A> 7456160	Jan 09, 2021	U-2163			
	>A> 7456160	Jan 09, 2021	U-2504			
	>A> 7456160	Jan 09, 2021	U-596			
	>A> 7456160*PED	Jul 09, 2021				
	>A> 8329680	Jan 09, 2021	U-1826			
	>A> 8329680	Jan 09, 2021	U-2108			
	>A> 8329680	Jan 09, 2021	U-2163			
	>A> 8329680	Jan 09, 2021	U-2504			
	>A> 8329680	Jan 09, 2021	U-596			
	>A> 8329680*PED	Jul 09, 2021				
	>A> 8466139	Jan 09, 2021	U-1826			
	>A> 8466139	Jan 09, 2021	U-2108			
	>A> 8466139	Jan 09, 2021	U-2163			
	>A> 8466139	Jan 09, 2021	U-2504			
	>A> 8466139	Jan 09, 2021	U-596			
	>A> 8466139*PED	Jul 09, 2021				
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002					M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	>A> 10220155	Jul 17, 2026	DP			
	>A> 7686786	Aug 03, 2026	DP	Y		
	>A> 7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
	>A> RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	>A> 7361649	Feb 22, 2026	DS DP U-1694		>A> NCE	Apr 15, 2020
	>A> 7361649*PED	Aug 22, 2026			>A> PED	Oct 15, 2020
	>A> 7361650	Feb 22, 2026	DS DP U-1694			
	>A> 7361650*PED	Aug 22, 2026				
	>A> 7867996	Feb 22, 2026	DS DP U-1694			
	>A> 7867996*PED	Aug 22, 2026				
	>A> 7879842	Feb 22, 2026	DS DP U-1694			
	>A> 7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	>A> 7361649	Feb 22, 2026	DS DP U-1694		>A> NCE	Apr 15, 2020
	>A> 7361649*PED	Aug 22, 2026			>A> PED	Oct 15, 2020
	>A> 7361650	Feb 22, 2026	DS DP U-1694			
	>A> 7361650*PED	Aug 22, 2026				
	>A> 7867996	Feb 22, 2026	DS DP U-1694			
	>A> 7867996*PED	Aug 22, 2026				
	>A> 7879842	Feb 22, 2026	DS DP U-1694			
	>A> 7879842*PED	Aug 22, 2026				
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> 10206877	Apr 14, 2035	DP U-2498			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861 001					NCE	Nov 26, 2023
<u>LAROTRECTINIB - VITRAKVI</u>						
N 210861 002					NCE	Nov 26, 2023
<u>LAROTRECTINIB - VITRAKVI</u>						
N 211710 001					NCE	Nov 26, 2023
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	>A> 10174017	Jan 27, 2030	DS DP U-1524		>A> NC	Mar 12, 2022
	>A> 8394826	Nov 10, 2030	DS DP U-1524		>A> NCE	Dec 18, 2022
	>A> 8450344	Jul 11, 2026	DS DP U-1524			
	>A> 9096569	Jul 11, 2026	DS DP U-1524			
	>A> 9415043	Mar 14, 2034	DS			
	>A> 9931336	Mar 14, 2034	DS DP U-1524			
	>A> 9993470	Mar 14, 2034	DS DP U-1524			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982			
	7468363	Oct 07, 2023	U-1983			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	>A> 8962630	Dec 09, 2029	U-1981			
	>A> 8962630	Dec 09, 2029	U-2505			
	>A> 9416136	Aug 20, 2029	U-1981			
	>A> 9416136	Aug 20, 2029	U-2505			
	>A> 9868739	Nov 09, 2031	U-1981			
	>A> 9868739	Nov 09, 2031	U-2505			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	>A> 7762994	May 23, 2024	DP			
	>A> 8579869	Jun 30, 2023	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	>A> 10226471	Aug 31, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	>A> 10231927	Jan 02, 2033	U-1349			
	>A> 10231927	Jan 02, 2033	U-1699			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			
	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 10039719	Dec 16, 2019	U-2357			
	>A> 10039719*PED	Jun 16, 2020				
	>A> 6419960	Dec 16, 2019	DP			
	>A> 6419960*PED	Jun 16, 2020				
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7083808*PED	Jun 16, 2020				
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7247318*PED	Jun 16, 2020				
	>A> 7438930	Dec 16, 2019	DP	Y		
	>A> 7438930*PED	Jun 16, 2020				
	>A> 8580310	Dec 16, 2019	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 8580310*PED	Jun 16, 2020				
	>A> 9066869	Dec 16, 2019	DP			
	>A> 9066869*PED	Jun 16, 2020				
	>A> 9801823	Dec 16, 2019	DP			
	>A> 9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		>A> NP	Feb 27, 2022
	9974752	Oct 30, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	>A> 10231983	Aug 22, 2038	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	>A> 10220158	Mar 20, 2035	DP U-2500			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	>A> 10143792	May 24, 2031	U-2476			
	>A> 10220158	Mar 20, 2035	DP U-2500			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001 >A>	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001 >A>	10233154	Sep 25, 2035	DS			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPENIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001 >A>	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002 >A>	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003 >A>	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001 >A>	5856336	Dec 25, 2020	DS U-998			
	>A> 5856336*PED	Jun 25, 2021				
	>A> 7022713	Feb 19, 2024	U-998			
	>A> 7022713*PED	Aug 19, 2024				
	>A> 8557993	Feb 02, 2024	DP			
	>A> 8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002 >A>	5856336	Dec 25, 2020	DS U-998			
	>A> 5856336*PED	Jun 25, 2021				
	>A> 7022713	Feb 19, 2024	U-998			
	>A> 7022713*PED	Aug 19, 2024				
	>A> 8557993	Feb 02, 2024	DP			
	>A> 8557993*PED	Aug 02, 2024				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	>A> 5856336	Dec 25, 2020	DS U-998			
	>A> 5856336*PED	Jun 25, 2021				
	>A> 7022713	Feb 19, 2024	U-998			
	>A> 7022713*PED	Aug 19, 2024				
	>A> 8557993	Feb 02, 2024	DP			
	>A> 8557993*PED	Aug 02, 2024				
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	>A> RE47301	Feb 02, 2027	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 10220155	Jul 17, 2026	DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	>A> 10213400	Mar 15, 2033	U-2499			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	9913860	Oct 22, 2033	DS U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	9913860	Oct 22, 2033	DS U-2312			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	>A> 10220155	Jul 17, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001 >A>	10232061	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	Jul 01, 2025	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-37	Dec 21, 2019
	5789379*PED	Oct 14, 2020			PED	Jun 21, 2020
	7056886	Sep 18, 2022	DP U-1320			
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	>A> 8241664	Mar 29, 2029	DP U-2506			
	>A> 8492369	Dec 20, 2030	DP U-2506			
	>A> 8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	>A> 8241664	Mar 29, 2029	DP U-2506			
	>A> 8492369	Dec 20, 2030	DP U-2506			
	>A> 8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	>A> 8241664	Mar 29, 2029	DP U-2506			
	>A> 8492369	Dec 20, 2030	DP U-2506			
	>A> 8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001				>A> CGT		Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002				>A> CGT		Oct 02, 2019



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	003				>A> CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	004				>A> CGT	Oct 02, 2019
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	001	>A> RE46284 >A> RE46284	Dec 16, 2026 Dec 16, 2026	U-1751 U-2503	>A> I-794 >A> ODE-229	Feb 24, 2022 Feb 22, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	002	>A> RE46284 >A> RE46284	Dec 16, 2026 Dec 16, 2026	U-1751 U-2503	>A> I-794 >A> ODE-229	Feb 24, 2022 Feb 22, 2026
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711	001				NCE >A> ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437	001	10166181	Feb 10, 2029	DP		
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956	001	10166181	Feb 10, 2029	DP		
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159	001	6258795	Jul 10, 2023	DP		
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169	001	6258795	Jul 10, 2023	DP		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	001	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	002	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	003	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282		
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962	004	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001				M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002				M-237 PED	Feb 22, 2022 Aug 22, 2022

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)